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 2 
Abstract 25 
 26 
Improvement of enzyme features is in many instances a pre-requisite for the industrial 27 
implementation of these exceedingly interesting biocatalysts. To reach this goal, the 28 
researcher may utilize different tools. For example, amination of the enzyme surface produces 29 
an alteration of the isoelectric point of the protein along with its chemical reactivity (primary 30 
amino groups are the most widely used to obtain the reaction of the enzyme with surfaces, 31 
chemical modifiers, etc) and even its “in vivo” behavior. This review will show some 32 
examples of chemical (mainly modifying the carboxylic groups using the carbodiimide route), 33 
physical (using polycationic polymers) and genetic amination of the enzyme surface. Special 34 
emphasis will be put on cases where the amination is performed to improve subsequent 35 
protein modifications. Thus, amination has been used to increase the intensity of the 36 
enzyme/support multipoint covalent attachment, to improve the interaction with cation 37 
exchanges supports or polymers, or to promote the formation of crosslinkings (both intra-38 
molecular and in the production of crosslinked enzyme aggregates). In other cases, amination 39 
has been used to directly modulate the enzyme properties (both in immobilized or free form). 40 
Amination of the enzyme surface may also pursue other goals not related with biocatalysis. 41 
For example, it has been used to improve the raising of antibodies against different 42 
compounds (both increasing the number of haptamers per enzyme and the immunogenicity of 43 
the composite) or the ability to penetrate cell membranes. 44 
Thus, amination may be a very powerful to improve the use of enzymes and proteins in many 45 
different areas and may be expected a great expansion of its usage in the next future. 46 
Key words: enzyme chemical amination, enzyme genetic amination, polymer coating of 47 
enzymes, enzyme multipoint covalent attachment, crosslinking, enzyme stabilization, enzyme 48 
modulation. 49 
 3 
Introduction 50 
 51 
 Enzyme features, such as specificity, selectivity and activity under mild conditions, 52 
have attracted the attention of researchers on theses molecules as catalysts of industrially 53 
relevant reactions since the middle of the last century.1-4 However, together with the positive 54 
properties, enzymes also have some features that are in opposition with their use as industrial 55 
catalysts: e.g., enzymes are soluble, unstable, inhibited by substrates, products and other 56 
compounds, and the good catalytic properties are only optimized towards the physiological 57 
substrate.5 Many of these limitations are based on their biological origin. In nature enzymes 58 
are submitted to strict regulations in complex metabolic routes to give a rapid answer to 59 
changes in the medium. However, now we intend to use the enzymes in an industrial reactor, 60 
where they are no longer required to have this regulative behavior. 61 
 Genetic tools have permitted to obtain more stable and efficient biocatalysts by 62 
diverse tools, such as site-directed mutagenesis or directed evolution.6-9 This strategy may be 63 
more or less complex and time-consuming to produce the desired enzyme, but once the mutant 64 
enzyme is ready, the large scale production will not be more expensive than using a native 65 
enzyme (it may become cheaper if enzyme overproduction is achieved. (Figure 1) 66 
 Another useful tool to improve enzyme properties is the chemical modification of 67 
enzymes.10-15 (Figure 2) Chemical modification may pursue producing a one-point 68 
modification (and although the effect of the modification on the enzyme features may be hard 69 
to predict, in some cases enzyme performance improves)16, 17 or the introduction of 70 
intramoleular crosslinkings to increase the enzyme rigidity and thus, enzyme stability may be 71 
enhanced.18 On one hand, the modification may be performed quite rapidly, but the enzyme 72 
will need to be modified each time the biocatalyst is prepared. On the other hand, as an 73 
additional advantage to genetic modifications, the only limit to the nature of the introduced 74 
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groups will be the imagination of the researcher, and it is not limited to enzymes with 75 
available genes.14, 15 76 
 Another tool to improve enzyme performance is the immobilization.19-25 This 77 
technique needs to be used to solve the first of the protein problems as industrial biocatalyst: 78 
the water-soluble nature of enzymes.26-28 (Figure 3). This consists in the confinement of the 79 
enzyme molecules in a limited space, and permits to have a heterogeneous catalyst, easy to 80 
separate from the reaction medium, and to reuse it, if the enzyme is stable enough. There are 81 
many immobilization techniques,29, 30 more or less adequate for each specific case depending 82 
on the enzyme and the process (e.g., substrate size).31 However, as this immobilization step is 83 
almost compulsory in the preparation of an industrial biocatalyst, many authors are trying to 84 
solve other enzyme limitations during immobilization.19-25 Thus, immobilization inside porous 85 
structures avoids the interaction of the enzyme molecules with other enzyme molecules 86 
(preventing enzyme aggregation) or with interfaces such as gas bubbles, able to inactivate 87 
enzymes25 (Figure 3). Rigidification of the enzyme tridimensional structure may be achieved 88 
via multipoint covalent attachment19-21, while the multisubunit immobilization of multimeric 89 
enzymes prevents their inactivation via dissociation.32 In some cases, the generation of 90 
favorable environments may permit the stabilization of the enzyme under certain conditions.33, 91 
34 (Figure 3). 92 
 With a handful of exceptions, these three tools are used in an individual way to 93 
design a biocatalyst, without considering that all of them may (and even must) be used 94 
simultaneously to have a biocatalyst with enhanced properties.35-37 This is even more stressed 95 
considering, as stated above, that the enzymes must be finally used in an immobilized form.26  96 
For example, the more stable the free enzyme is, the higher the range of conditions that may 97 
be used to submit the enzyme to immobilization or chemical modification processes.36 98 
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In fact, the relevant point is the final stability of the immobilized enzyme, and not the 99 
stability of the free enzyme (Figure 4).  100 
In this review, we will focus on the amination of the enzyme molecule surface, using 101 
physical, chemical or genetic strategies, to improve its properties, such as stability, but also 102 
activity or selectivity. Special emphasis will be paid to the coupled use of amination to 103 
improve the immobilization, chemical or physical modifications of the enzyme. 104 
 105 
2. Importance of the amination of enzyme surface 106 
The amination of the surface of a protein may fulfill many different objectives (Figure 107 
5). For example, it may alter the existing interactions between the groups in the enzyme 108 
support to tune the enzyme properties.35 This is easily obtained using chemical modification 109 
because chemical amination is based on the amidation of carboxylic acids (see section 110 
below).38, 39 This modification produces a clear alteration of the ionic interactions on the 111 
protein surface: ionic bridges may be broken and changed by repulsion forces. These changes 112 
may affect the conformation of the enzyme, and thus its stability, activity, specificity or 113 
selectivity.40, 41 114 
 This alteration of the sign in the ionic character of areas of the protein surface may 115 
facilitate the use of cation exchangers to purify the enzyme that does not naturally have  116 
tendency to become adsorbed on these supports (e.g., using poly-Lys tags).42-44 117 
 Another likely objective to be achieved via amination of the enzyme surface is to 118 
increase the enzyme chemical reactivity versus a support used for covalent immobilization.37 119 
Most of the supports used to immobilize proteins are designed to involve the primary amino 120 
groups of the protein (terminal amino group and ε amino group of Lys). That is because Lys is 121 
an ionic nucleophilic group, relatively frequent in the enzyme sequence, usually placed on the 122 
protein surface due to its hydrophilicity and its reactivity with a broad diversity of groups that 123 
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may be introduced in the support (epoxyde,45-47 vinyl sulfone,48, 49 glutaraldehyde,50, 51 124 
cyanogen bromide,52 tosyl chloride,53 tresyl chloride,54 glyoxyl,55 etc.) without requiring any 125 
activation step. As a first obvious effect, an enrichment of the enzyme surface in primary 126 
amino groups will produce an increase on the immobilization rate of all these supports. 127 
Introduction of Lys residues may also permit the immobilization/purification of the enzyme, 128 
using supports such as glyoxyl ones that require immobilizing the enzyme via some 129 
enzyme/support attachments.56, 57 130 
 However, as it will be discussed in a following section, the main interest of this 131 
modification is the possibility of achieving a more intense enzyme/support reaction,35, 37 that 132 
is, a more intense multipoint covalent attachment that can drive to higher enzyme stabilization 133 
, or controlling the immobilization area (in this case, just using site-directed mutagenesis).58, 59 134 
 If the amino groups are introduced chemically using ethylendiamine, the new amino 135 
groups present a pK value that is lower than that of the Lys (9.2 versus 10.7),60 being thus 136 
more reactive and permitting both, immobilization and multipoint covalent attachment under 137 
milder conditions.35 This may be very important when the enzyme is unstable at alkaline pH 138 
values.61 However, this modification will be uncontrolled along the whole protein surface, 139 
while the site directed mutagenesis permits to introduce reactive groups just in the desired area 140 
of the protein, leaving the other areas of the protein unmodified. 141 
 The increase of amino groups in the enzyme surface may also be a tool to facilitate 142 
some further chemical or physical modification of the enzyme. For example, it may facilitate 143 
the coating of the enzyme with anion exchangers.62, 63 The increase on primary amino groups 144 
has been  also used in certain cases to improve the prospects of achieving intra (to stabilize 145 
enzymes)64 or intermolecular (to prepare crosslinked enzyme aggregates, CLEAs).65 The 146 
lower pK value of the chemically introduced amino groups using ethylenediamine has also 147 
permitted to have a more general chemical modification of protein surfaces with other 148 
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molecules via modification of these amino groups under mild conditions that requires using 149 
the unmodified enzyme.66 150 
 The physical coating of the enzyme surface with a poly-amine polymer, like 151 
polyethylenimine or poly allyl amine, will have many positive effects on enzyme properties, 152 
effects that are derived from the physical and chemical features of the polymer67-69. Among 153 
these, we can remark out the partition away from the enzyme environment of deleterious 154 
hydrophobic compounds (oxygen,70, 71 hydrophobic organic cosolvents,72, 73 prevention of 155 
interaction with inactivating interfaces,74 stabilization of multimeric structures,74, 75 etc).   156 
However, in the context of this review, it be remarked that the coating with poly-amine 157 
polymers of the enzyme surface permits, in an indirect way, the enzyme ionic exchange on a 158 
cation exchanger, even though initially the enzyme had no tendency to become adsorbed to 159 
this cation exchanger.74 160 
In the next sections of this review, we will present and discuss in a deeper way all this 161 
general ideas, supplying some of the available examples. 162 
 163 
3. Chemical amination  164 
3.1. Chemisytry of the chemical amination of enzymes using the carbodiimide route 165 
The use of water-soluble carbodiimides in conjunction with reactive nucleophilic 166 
species, as a technique for the modification of carboxyl groups in enzymes and other proteins, 167 
was introduced several years ago.76, 77 Proteins have many reactive groups that can react 168 
largely with carbodiimides in the same fashion as with simple nucleophiles.78 Versatility and 169 
usefulness of carbodiimides as chemical modifying agents has been widely demonstrated.41, 61, 170 
78-80 171 
Ethyl-di-methyl-amino-propyl Carbodiimide (EDC) is often used in the chemical 172 
modification of biocatalysts, such as proteases, ribonuclease and glucose oxidase, among 173 
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others, and allows the alteration of amino acid side chains thereby generating new enzymes 174 
via covalent modification of existing proteins. For this reason it has been used extensively for 175 
the chemical modification of proteins.38, 78, 80  176 
Using carbodiimides and nucleophiles such as primary amines it is possible to modify 177 
carboxyl groups from different proteins. The nature of the current chemical reactions involved 178 
in carboxyl group modifications using water-soluble carbodiimides has been previously 179 
described.77, 81 This chemistry is summarized in Figure xx.  In the first step of the reaction, the 180 
carboxyl group is added to the carbodiimide, forming a very labile O-acyl-iso-urea 181 
intermediate. As a result of the re-protonation at the site of the Schiff base, the intermediate 182 
will change into a carbocation, followed by reaction with nucleophilic species such as 183 
ethylenediamine at high concentrations in order to give a stable amide bond (Figure XX, route 184 
1).  185 
On the other hand, if carbodiimide is added in excess, the O-acyl-iso-urea intermediate 186 
can be rearranged to form N-acyl-urea as byproduct via an intramolecular acyl transfer 187 
mechanism. In the special case, where the nucleophile is water, the carboxyl group will be 188 
regenerated with the conversion of 1 molecule of carbodiimide into its corresponding urea 189 
(Figure XX, route 2).77, 81 However, kinetic studies on the modeling of carbodiimide-carboxyl-190 
nucleophile system have shown that the rearrangement can be slowly compared to the 191 
nucleophilic attack if the concentration of nucleophile is sufficiently high.77 Therefore, the 192 
coupling reaction of carboxyl and nucleophile can be driven essentially to completion in the 193 
presence of excess of both carbodiimide and the nucleophilic reagent. 194 
Carbodiimides are not only specific for carboxyl groups. In aqueous solutions at acidic 195 
pHs, carbodiimides would react also with free sulfhydryl groups as for example the thiol 196 
group from side chains of cysteine,82 as well as accessible phenolic hydroxyl groups and 197 
tyrosines.83 Indeed, it has been reported that the carbodiimide activated O-acyl-iso-ureas on 198 
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one molecule may undergo displacement by the slightly nucleophilic hydroxyl of tyrosine 199 
(Figure 3).80, 83, 84 In fact, kinetic studies have shown that reaction rates of sulfhydryl and 200 
carboxyl groups with EDC are approximately equal, while tyrosine reacts more slowly. 201 
Carraway and Koshland83 have shown that EDC converts accessible tyrosine residues in 202 
proteins to O-arylisourea derivatives, which are resistant towards acid hydrolysis. However, 203 
they have also shown that hydroxaminolysis of the modified protein quantitatively reverses 204 
this tyrosine modification. 205 
The reaction of carbodiimides with the carboxyl group in proteins can lead to 206 
inhibition; this can be caused by interaction of neighboring nucleophiles that could generate 207 
intramolecular cross-linkings (Figure xxa). For example, ATPase is inhibited by the 208 
carbodiimide. The mechanism of the inhibition is thought to be via formation of the O-acyl-209 
iso-urea species followed by the attack of an adjacent nucleophile causing the loss of urea, 210 
covalent binding of the nucleophile with the binding site to produce cross-linking, and no loss 211 
of inhibition. Protection of the enzyme by methyl glycinate only occurs when this nucleophile 212 
is added simultaneously with the carbodiimide; subsequent addition to the nucleophile does 213 
not cause regeneration of the O-acyl-iso-urea.78, 85  214 
Furthermore, another cause of enzymatic inhibition by use of carbodiimides can be 215 
attributed to O-N-acyl shift re-arrangements (figure xxxb). If the external nucleophile is water, 216 
tthe enzyme is then regenerated. The O-acylisourea is relatively labile to hydrolysis, which 217 
causes regeneration of the active enzyme. However, residues partially shielded from 218 
solvolysis are susceptible to the stable N-acyl-urea rearrangement. Functionally important acid 219 
groups may frequently be found shielded in active sites and this type of chemical modification 220 
becomes now feasible.78, 84  221 
 222 
3.2. Chemical amination of free enzymes  223 
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 The amination of enzymes via the carbodiimide route is a very old technology. The 224 
first interest of the modifications is usually the modification of the carboxylic acids of the 225 
protein to discriminate the existence of essential carboxylioc groups for the function of the 226 
proteins, and that was performed with diamines,79 but also with just mono amine 227 
compounds80, 86 as the final goal was not the amination of the enzyme surface but the 228 
modification of the carboxylic residues. 229 
 However, some examples may be found where the objective was to aminate the 230 
enzyme surface and check the effects of this modification on the enzyme performance.  231 
 One of the first approaches in using diamines and carbodiimide to improve enzyme 232 
properties was the test of using modification to introduce   intramolecular cross-linkages.87 233 
The effect of the length of the diamine chain on the thermostability of α-chymotrypsin has 234 
been studied. To increase the prospects of having an intense crosslinking, α-chymotrypsin was 235 
succinylated. For succinylated α-chymotrypsin, the dependence of the rate constant of 236 
monomolecular thermoinactivation of the enzyme on the length of the cross-linking agent has 237 
a minimum for a shorter bifunctional reagent, ethylenediamine.The maximum stabilizing 238 
effect (compared to the native enzyme) increased (from 3- to 21-fold) when α-chymotrypsin 239 
was modified with tetramethylenediamine or succinylated α-chymotrypsin modified with 240 
ethylenediamine is used.87 However, they did not check if the amination degree was similar 241 
using the different diamines (and very likelt it was not, due to the different pK of the amino 242 
groups), neither checked the likely existence of enzyme aggregates. 243 
 In a further research, the modification of 3 carboxyl groups of the glucoamylase 244 
from Aspergillus niger by ethylenediamine l increased the thermostability of the enzyme for 245 
temperatures above the temperature of compensation, which is 60 °C.88 246 
 In some exapmles, a specific modificacion of a target carboxilic residue could be 247 
achieved if the cardodiimide presented some affinity towards those groups. This was the case 248 
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of the specific modificacion of Asp-101 of hen egg white lysozyme, via the carbodiimide 249 
route, and using nucleophiles as different as ethanolamine, ethylenediamine, methylamine, or 250 
4(5)-(aminomethyl)imidazole. The specific modificaiton could be attained using a small 251 
excess of carbodiimide, and that was explained by the specific binding of EDC to the substrate 252 
binding site close to Asp-101.89, 90 With histamine or D-glucosamine, the selectivity of the 253 
modification towards Asp-101 was somewhat lower. This may be due to the specific binding 254 
of these amines to lysozyme in competition with the carbodimide. Depending on the amine 255 
employed, the modified lysozyme exhibited a decreased activity (83-52% of native enzyme), 256 
suggesting that the modification of Asp-101 weakened substrate binding.  257 
 In another example, the carboxyl groups of β-glucosidase from Aspergillus niger 258 
NIAB280 were modified by water soluble 1-ethyl-3(3-dimethylaminopropyl) carbodiimide  in 259 
the presence of glycinamide or ethylenediamine.91 The half-lives of both modified enzymes at 260 
low temperatures (55 and 60°C) were reduced, whereas at higher temperatures (64 and 67°C) 261 
half-lives were enhanced. At 70°C the half-life of the enzyme modified with glycinamide 262 
became equal to the native whereas that of the EDA modified enzyme was increased. 263 
Chemical amination may produce very different effects when changing the inactivation 264 
conditions. 265 
 In some instances, amination was not the target reactions but a reference composite. 266 
Carboxymethylcellulase from Aspergillus niger was modified by 1-ethyl-3(3-267 
dimethylaminopropyl) carbodiimide in the presence of dimethylamine hydrochloride and 268 
ethylenediamine dihydrochloride as nucleophiles.92 The amino groups of the enzyme modified 269 
with dimethylamine hydrochloride were further modified by acetic anhydride for the complete 270 
elimination of surface charges. In all cases the specificity constants (V(max)/K(m)) was 271 
improved from 0.16 to around 1. Gibbs activation free energies of denaturation of native and 272 
aminated enzyme at 80ºC and pH 5.2 were 110 and 107 kJ mol-1, whereas enthalpy of 273 
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denaturation were 143 and 144 kJ mol -1, and the entropies of denaturation were 91 and  105 274 
kJ mol-1 K-1, respectively, indicating highly disordered conformations of all the transition 275 
states of modified enzyme. However, the authors focused on the stabilization of the double 276 
modified enzyme in the presence of solvents.92  277 
 Chemical amination using ethylenediamine of a glucoamylase from Fusarium solani 278 
permitted to increase activity and stability of the enzyme, being the effect depended on the 279 
exact modification degree.93 Temperature and pH optima of modified glucoamylase increased 280 
after modification while the specificity constant (k cat/K m) of unmodified and optimal 281 
modified enzyme went from 136 to 225. Thus, the chemical amination of this enzyme offered 282 
vey interesting enhances of the enzyme performance. 283 
 Three to four carboxyl groups of a xylanase from Scopulariopsis sp. were 284 
chemically modified using ethylendiamine and carbodiimide.94, 95 There were no differences 285 
in pH optima between the native and modified enzyme, but there was a double pH optimum 286 
for the modified enzyme. The Vmax/Km decreased relative to the non-modified enzyme. 287 
 In a very interesting paper, Matsumoto and co-workers showed the combined use of 288 
chemical modification and site-directed mutagenesis to get an optimized enzyme. The target 289 
enzyme was serine protease subtilisin Bacillus lentus A significant enhancement of the 290 
applicability of this enzyme in peptide synthesis was achieved by using the strategy of 291 
combined site-directed mutagenesis and chemical modification to create chemically modified 292 
mutant  enzymes.96 The introduction of polar and/or homochiral auxiliary substituents, such as 293 
X = oxazolidinones, alkylammonium groups, and carbohydrates at position 166 at the base of 294 
the primary specificity S 1 pocket created  an enzyme with strikingly broad structural substrate 295 
specificities. These modified mutante enzymes are capable of catalyzing the coupling 296 
reactions of not only L-amino acid esters but also D-amino acid esters as acyl donors with 297 
glycinamide to give the corresponding dipeptides in good yields. These powerful enzymes are 298 
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also applicable to the coupling of L-amino acid acyl donors with L-alaninamide. Typical 299 
increases in isolated yields of dipeptides of 60-80% over the wild type enzyme (e.g. 0% yield 300 
of Z-D-Glu-GlyNH 2 using wild type enzyme versus 74% using S166C-S-(CH 2) 2 NMe 3 +) 301 
demonstrate the remarkable synthetic utility of this "polar patch" strategy. Such wide-ranging 302 
systems displaying broadened and therefore similarly high, balanced yields of products (e.g. 303 
91% Z-L-Ala-GlyNH 2 and 86% yield of Z-D-Ala-GlyNH 2 using S166C-S-(3R,4S)-304 
indenooxazolidinone) was proposed as a tool to allow the use of biocatalysts in parallel library 305 
synthesis.96 306 
 In another cases, the covalent modification of the enzyme was carried out using 307 
polymers. For example, chitosan was linked to invertase by covalent conjugation to periodate-308 
activated carbohydrate moieties of the enzyme.97 The thermostability of the modified enzyme 309 
was enhanced by about 10 ºC. The half-life at 65 ºC was increased from 5 min to 5 h. The 310 
enzyme stability was enhanced by 20% at pH below 3.0. The half-life of denaturation by 6 M 311 
urea was increased by 2 h. 312 
 In another instance, the sugar chain of glycosilated portion was aminated before a 313 
further modification. For example, pectin was attached to ethylenediamine-activated 314 
carbohydrate moieties of invertase using 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide as 315 
coupling agent.98 The modified enzyme retained 57% of the original activity and contained 2.7 316 
mol polymer per mol of holoenzyme. Its optimum temperature was increased by 8 ºC and its 317 
thermostability by 7.3 ºC. The half-life at 65 ºC was increased from 5 min to 2 days. The 318 
enzyme stability was enhanced by 33 % at pH 2.0, and also by 27 % at pH 12.0. The 319 
conjugate retained about 96 % of its initial activity after 3 h incubation in 6 M urea. 320 
 A more sophisticated strategy involves the use of an enzyme to produce the chemical 321 
modification of the target enzyme with the aminated polymer. Several polysacharides were 322 
derivatized with 1,4-diaminobutane and covalently attached to bovine pancreatic trypsin 323 
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through a transglutaminase-catalysed reaction.99 The conjugates retained about 61–82% of the 324 
original esterolytic activity of trypsin, while the optimum pH was shifted to alkaline values. 325 
The prepared conjugates were also more stable against thermal incubation at different 326 
temperatures ranging from 50ºC to 60ºC, and were about 22- to 48-fold more resistant to 327 
autolytic degradation at pH 9.0. Transglutaminase-catalysed glycosidation also protected 328 
trypsin against denaturation in surfactant media, with 9- to 68–fold increased half-life times in 329 
the presence of 0.3% (w/v) sodium dodecylsulfate. 330 
 331 
3.3. Chemical amination to improve the immobilization of the enzyme 332 
 3.3.1. Increase of the intensity of the enzyme/support multipoint covalent 333 
attachment  334 
 As stated above, one of the goals that may be pursued by amination of the enzyme 335 
surface is to increase the amount of reactive groups on the enzyme surface and thus improve 336 
the prospects of getting an intense multipoint covalent attachment. It is possible to find diverse 337 
examples of this in the literature. However, this strategy may be effective only if the support 338 
and protocol are chosen in a way that may permit to get this multipoint covalent attachment 339 
(e.g., glyoxyl-agarose,55 epoxy,50 etc). 340 
 The first example was the amination of the enzymes glutarayl acylase and penicillin 341 
G acylase to improve their multipoint covalent immobilization on glyoxyl-agarose.100 Both 342 
enzymes were quite different regarding the density of Lys residues on the surface. While 343 
penicillin G acylase presented 41 superficial Lys,101 glutarayl acylase presented just 9 344 
groups.102 In fact, penicillin G acylase could be greatly stabilized via immobilization on 345 
glyoxyl agarose, while glutarayl acylase immobilized very slowly in this support and the 346 
stabilization obtained was reduced. After full chemical amination of the exposed carboxylic 347 
groups (following the carbodiimide route described above), it was found that the aminated 348 
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penicillin acylase almost did not reduce its activity, but severely reduced enzyme stability. For 349 
this reason, only 50% modification was utilized. In the case of glutarayl acylase the lack of 350 
stability at pH 4.75 forced to use pH 6 in the modification and after this the activity decreased 351 
by 20%, but its stability remained almost unaltered. This shows the heterogeneity of the 352 
effects of the chemical modification on enzyme properties, as it has been shown above. 353 
Moreover, it also suggests that the chemical modification may be at a disadvantage regarding 354 
the genetic modification, where only the desired groups will be modified. 355 
 As a further advantage, both enzymes could be now immobilized at pH 9 (while the 356 
non aminated enzyme required a pH value near 10). This permitted to alter the orientation of 357 
the enzymes on the enzyme support and after immobilization at pH 9, the pH was increased to 358 
10 to favor the multipoint covalent attachment. For glutarayl acylase, results were similar to 359 
the direct immobilization at pH 10, but for penicillin G acylase, the stability increased by a 2-360 
fold factor compared to the enzyme directly immobilized at pH 10. Thus, after immobilization 361 
of the partially animated enzymes, the comparison of the unmodified/ modified enzymes 362 
immobilized on glyoxyl support permitted to get a stabilization of a four-fold factor in the 363 
case of penicillin G acylase and a 20-fold factor in the case of glutarayl acylase, showing the 364 
potential of the strategy.100  365 
 Glucoamylase immobilized very slowly on glyoxyl-agarose, stabilizing the enzyme 366 
only by a 6-fold factor.103 After amination, enzyme stability was maintained, but now the 367 
immobilization rate was higher and the final stabilization factor was 500, maintaining a 50% 368 
of the initial activity after the whole protocol. 369 
 Laccase from Trametes versicolor was aminated and immobilized on glyoxyl 370 
supports, enabling a stabilization of 280 folds while maintaining a 60% of the activity.104 371 
Without the amination step, the immobilization of the enzyme on the support results 372 
negligible, due to the poor density of Lys residues on the enzyme surface (just 8 Lys).105 This 373 
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biocatalyst could be used 10 cycles in oxidation of phenyl compounds without detecting a 374 
decrease in enzyme activity. 375 
 Immobilization of lipase from Candida rugosa on electrochemically synthesized 376 
PANI activated with glutaraldehyde could be improved after chemcial amination of the 377 
enzyme.106 Aminated lipases exhibited higher specific activity (52%) and thermal stability (3 378 
times) after immobilization, compared with the unmodified lipase. Also, reusability of the 379 
immobilized enzyme was significantly increased with amination, especially if immobilization 380 
was performed at pH 10, this biocatalyst retained 91% of activity after 15 reaction cycles. 381 
 The effect of different chemical modifications, before or after immobilization, on the 382 
properties of immobilized invertase from baker's yeast immobilized was studied.107 The 383 
immobilized preparations obtained were Sp-INV by direct coupling of invertase to Sepharose, 384 
Sp-PEA-INV by coupling of periodate and ethanolamine-treated invertase to Sepharose, Sp-385 
PEDA-INV by coupling of periodate and ethylenediamine-treated invertase to Sepharose, and 386 
Sp-PEDA-2-4-6-trinitrobenzene sulfonic acid (TNBS)-INV by coupling of TNBS followed by 387 
periodate and ethylenedianzine-treated invertase to Sepharose. All of the immobilized 388 
preparations exhibited higher stability against heat and urea-induced inactivation as compared 389 
to native invertase. Among the procedures employed for immobilization of invertase, the Sp-390 
PEDA-INV preparation exhibited highest yield of immobilization, and thermal and storage 391 
stability.  392 
 However, this strategy was complicated for industrial implementation, as it requires 393 
the complete elimination of the remaining ethylenediamine, a competitor for the glyoxyl 394 
groups that could reduce the prospects of getting an intense multipoint attachment.  The use of 395 
free enzyme makes the use of more or less complex techniques (e.g., ultrafiltration) necessary 396 
to eliminate this reagent. This was solved in a new evolution of the strategy. The target 397 
enzymes were lipases, which could be reversibly immobilized on octyl-agarose,108 a support 398 
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that did not produce any cross-reaction. These immobilized enzymes were aminated in solid 399 
phase, washed in a very simple fashion to eliminate the residual ethylenediamine, desorbed 400 
from the octyl-agarose beads using a detergent, and immobilized on glyoxyl-agarose.35 The 401 
presence of detergent was useful to avoid the risk of lipase/lipase aggregation during covalent 402 
immobilization.109, 110  403 
 In a first example, the lipase from Bacillus thermocatenulatus was used as model.111 404 
The enzyme is not very rich in external Lys residues.112 The chemical amination did not 405 
present a significant effect on the enzyme activity and only reduced the enzyme half-life by a 406 
3-4-fold factor in inactivations promoted by heat or organic solvents.  The optimal 407 
stabilization protocol was the immobilization of aminated BTL2 at pH 9 and the further 408 
incubation for 24 h at 25 °C and pH 10. This preparation was 5-fold more stable than the 409 
optimal BTL2 immobilized on glyoxyl agarose and around 1200-fold more stable than the 410 
enzyme immobilized on CNBr and further aminated. 411 
 In a further example, the lipase from Thermomyces lanuginosus was submitted to a 412 
similar treatment.61 The enzyme presented few external Lys groups,113 offering low prospects 413 
to get multipoint covalent attachment on glyoxyl supports. Even immobilization was quite 414 
slow. This case was even more complex, as the free enzyme at pH 10 was inactivated making 415 
its immobilization on glyoxyl agarose very complex, while at pH under 10 the enzyme was 416 
not immobilized. However, after amination, the enzyme could be rapidly immobilized at pH 9 417 
or 10, avoiding enzyme inactivation. This permitted to maintain 70 % of the enzyme activity 418 
with a 5-fold improved stability compared to the immobilized non-aminated enzyme (that also 419 
presented very low activity recovery). This stabilized enzyme showed its good performance in 420 
some reactions such as the production of biodiesel,114, 115 hydrolysis of sucrose laurate,116 and 421 
synthesis of ascorbyl oleate by transesterification of olive oil with ascorbic acid in polar 422 
organic media.117  It was also shown that the aminated and multipoint covalently attached 423 
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enzyme could be unfolded and refolded even in a more efficient fashion than the unmodified-424 
one point immobilized enzyme.118 425 
 In another research, octyl-agarose immobilized lipase from Rhizomucor miehei was 426 
aminated and immobilized on glyoxyl-agarose and cyanogen bromide-agarose.119 Results in 427 
stability were not analyzed, but the immobilization rate was higher in glyoxyl agarose (even 428 
using pH 9.1 for the aminated enzyme). However, using the cyanogen bromide-agarose 429 
immobilization rate was slower for the aminated enzyme that was not explained by the 430 
authors. Using diothitritol (to stabilize the one-point imino bonds with the support) the 431 
aminated enzyme could be immobilized even at pH 8.120 432 
 433 
 3.3.2. Improved production of crosslinked enzyme aggregates 434 
 Crosslinked enzyme aggregates (CLEAs) is a relatively recent immobilization 435 
technique developed the group of Prof Roger Sheldon.121, 122 The strategy is relatively simple, 436 
consisting on the precipitation of the enzyme in an active form and the physical stabilization 437 
of the aggregate articles via chemical crosslinking to prevent re-dissolution when the 438 
aggregation reagent is eliminated.123 However, in some instances, the crosslinking step of the 439 
enzyme may not be simple, e.g., if the enzyme has few reactive groups on its surface.124 The 440 
amino groups tend to be the most utilized groups for crosslinking.113, 114 Co-aggregation of the 441 
enzyme with other Lys rich proteins is one of the possible solutions,125-127 as well as the use of 442 
PEI (see section 4 of this review).128, 129 However, both strategies reduce the volume loading 443 
of the target protein on the final biocatalyst. The amination of the enzyme may be a simple 444 
solution to solve this problem. 445 
 This has been used, to date, in a single paper.65 Lipase B from Candida antarctica is 446 
not very adequate to prepare CLEAS due to the low amount of surface Lys.130 Although the 447 
precipitation step is easy using different precipitants, the cross-linking step becomes a 448 
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problem due to the low amount of Lys residues in this enzyme.65 The enzyme surface was 449 
enriched in amino groups by chemical amination of the enzyme using ethylenediamine and 450 
carbodiimide. Using this aminated enzyme, precipitation is also effective and the crosslinking 451 
step is no longer a problem. Stability of this CLEA was higher in both thermal and cosolvent 452 
inactivation experiments than that of the coCLEA produced by co-aggregation of BSA and 453 
enzyme;65 another alternative to produce a CLEA of this interesting enzyme.131  454 
 455 
 3.3.3. Improved immobilization on cation exchangers 456 
 Immobilization of proteins on ion exchaners requires the simultaneous establishment 457 
of several enzyme-support interactions.132-134 Most enzymes have an isoelectric point ranking 458 
from 4 to 5, and this makes that the enzymes can hardly become adsorbed on cation 459 
exchangers under a wide range of pH values. This may be facilitated if the carboxylic groups 460 
of the enzyme are modified to amino groups via chemical amination, as the number of cationic 461 
groups may be greatly increased and thus, the enzyme may become easily exchanged in 462 
anionic supports in a wide range of conditions. However, there are few examples of this 463 
strategy. The enzyme penicillin G acylase is not adsorbed at pH 7 on carboxymethyl or 464 
dextran sulfate-coated supports. The chemical amination of the protein surface permitted the 465 
immobilization of the enzyme on both anionic supports.62 Immobilization was very strong on 466 
these supports, mainly in the polymeric ones, and dependent on the degree of modification, 467 
although the enzymes can still become desorbed after inactivation by incubation under drastic 468 
conditions. Moreover, the immobilization on ionic polymeric beds allowed a significant 469 
increase in enzyme stability against the inactivation and inhibitory effects of organic solvents, 470 
very likely by the promotion of a certain partition of the organic solvent out of the enzyme 471 
environment. 472 
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 The chemical introduction of aminated polymers has also been used to improve the 473 
ionic exchange of proteins on ion exchangers. Invertase from Saccharomyces cerevisiae was 474 
chemically modified with chitosan and further immobilized on sodium alginate-coated chitin 475 
support. The positive charges of the chitosan permited to keep the enzyme retained by 476 
interactions with the anionic alginate. The yield of immobilized protein was determined as 477 
85% and the enzyme retained 97% of the initial chitosan-invertase activity.135 The optimum 478 
temperature for invertase was increased by 10 ºC and its thermostability was enhanced by 479 
about 9 ºC after immobilization. The immobilized enzyme was stable against incubation in 480 
high ionic strength solutions and was four-fold more resistant to thermal treatment at 65 ºC 481 
than the native counterpart. The biocatalyst prepared retained 80% of the original catalytic 482 
activity after 50 h under continuous operational regime in a packed bed reactor. The strategy 483 
was further extended to the immobilization of the modified enzyme on pectin-coated chitin 484 
support via polyelectrolyte complex formation.136 The yield of immobilized enzyme protein 485 
was determined as 85% and the immobilized biocatalyst retained 97% of the initial chitosan-486 
invertase activity. The optimum temperature for invertase was increased by 10°C and its 487 
thermostability was enhanced by about 10°C after immobilization. The immobilized enzyme 488 
was stable against incubation in high ionic strength solutions and was 4-fold more resistant to 489 
thermal treatment at 65 °C than the native counterpart. The biocatalyst prepared retained 96 490 
and 95 % of the original catalytic activity after 10 cycles of reuse and 74 h of continuous 491 
operational regime in a packed bed reactor, respectively.136  492 
 The same chemical modification strategy was used to immobilize this enzyme on 493 
hyaluronic-acid-modified chitin.137 The immobilized enzyme retained 80 % of the initial 494 
invertase activity. The optimum temperature for sucrose hydrolysis was increased by 5 ºC, and 495 
its thermostability was enhanced by about 10 ºC after immobilization. The immobilized 496 
enzyme was stable against incubation in high-ionic-strength solutions, and was six-fold more 497 
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resistant to thermal treatment at 65 ºC than the native counterpart.137 The biocatalyst prepared 498 
retained 100 % of the inicial activity after 10 cycles of reuse as well as after 74 h of 499 
continuous sucrose hydrolysis in a packed bed reactor, respectively.  500 
 501 
3.4- Chemical amination of immobilized enzymes to improve their catalytic performance 502 
 As previously discussed (point 3.2), the chemical amination of enzymes may be a 503 
potent tool to improve enzyme performance. As stated in point 3.3.1. of this review and 504 
discussed in,35 the chemical modification of enzymes in the solid phase has many advantages: 505 
prevention of aggregation, possibility of using stabilized enzymes, easy performance and 506 
control, etc. 507 
 Therefore, if the modification is performed to alter enzyme properties of an enzyme 508 
that is going to be used in an immobilized way, it makes sense to perform the modification on 509 
an already immobilized enzyme, 510 
 Most of the examples found using the chemical amination of the immobilized 511 
enzymes are quite recent. In one of the first examples, three different immobilized lipases 512 
[those from Candida antarctica (form B), Thermomyces lanuginosus and Pseudomonas 513 
fluorescens were modified with ethylenediamine.138 In some cases, the activity of the lipases 514 
increased after the chemical modification while in other cases the activity was strongly 515 
reduced. The enantioselectivity of the enzymes in the hydrolysis of different mandelic acid 516 
derivatives was also highly modulated. For example, amination of the CNBr-CAL-B 517 
preparation greatly increased the enantioselectivity of the enzyme in the hydrolysis of (±)-2-518 
hydroxyphenylacetic acid methyl ester, from an E value of 2 without modification up to 519 
E>100, affording (R)-mandelic acid in high purity (ee>99% at 50% conversion) at pH 7 and 520 
4°C. 521 
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Novozym 435 (a commercial immobilized preparation of lipase B from C. antarctica) 522 
was modified via aminoethylamidation among other compounds.139 The modified enzyme 523 
improved the activity versus 3-phenylglutaric dimethyl diester by around a two fold factor, 524 
while decreased the activity versus mandelic acid methyl ester or 2-O-butyryl-2-phenylacetic 525 
acid. However, the enantiospecificty of the enzyme in the hydrolysis of racemic mandelic acid 526 
methyl ester improved while the enantioselectivity in the hydrolysis of 3-phenylglutaric 527 
dimethyl diester. 528 
 The lipase from Thermomyces lanuginosus was immobilized on octyl Sepharose and 529 
further modified with ethylenediamine after activation of the carboxylic groups with 530 
carbodiimide.41 Different degrees of modification of the carboxyl groups were carried out by 531 
controlling the concentration of carbodiimide (10%, 50% or 100%). Interestingly, the 532 
chemical modification of the immobilized lipase produced an improvement in its activity 533 
versus p-nitrophylpropionate, and it increased with the modification degree. This increase in 534 
activity was much more significant at pH 10, where the fully modified preparation increased 535 
the activity by a factor of 10 as compared to the unmodified preparation. Moreover, the 536 
incubation of the chemically aminated preparations in a hydroxylamine solution (to recover 537 
modified Tyr residues) improved the activity by an additional factor of 1.2. The fully aminated 538 
and incubated enzyme in hydroxylamine preparation exhibited a higher thermostability than 539 
that of the unmodified preparation, mainly at pH 5 (almost a 30 fold factor). In the presence of 540 
tetrahydrofuran, some stabilization was observed at pH 7, while at pH 9 the stability of all 541 
modified enzymes decreased.41 542 
 In another example, three different lipases (from Candida antarctica fraction B, 543 
Thermomyces lanuginosa, and Rhizomucor miehei) were immobilized on CNBr-activated 544 
Sepharose via a mild covalent immobilization or adsorbed onto octyl-Sepharose and submitted 545 
to amination among other modifications, altering (and in some cases improving) the enzyme 546 
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performance in the selective hydrolysis of sardine oil to produce eicosapentaenoic acid and 547 
docosahexaenoic acid, being the lipase from Candida antarctica fraction B  the lipase with a 548 
lower change in its properties in this reaction.140  549 
 In a further extension of the strategy, the fact of the increase in amino groups in the 550 
surface of the protein was not the only target. As a second target, the fact that, now, the 551 
enzyme surface is enriched in amino groups was utilized to achieve a larger modification of 552 
the protein surface with a second amine-modifying reagent. Together to the potential to 553 
modulate enzyme properties of the chemical modifications, the research was also focused on 554 
the decisive effect that the immobilization protocol has on the effects of the chemical 555 
modifications. In a first example, Candida antarctica fraction B adsorbed on octyl-agarose or 556 
covalently immobilized on cyanogen bromide agarose was modified with ethylenediamine 557 
(EDA) or 2,4,6-trinitrobenzensulfonic acid (TNBS) using one reagent or using several 558 
modifications in a sequential way (the most complex preparation was CALB-TNBS-EDA-559 
TNBS).40 The covalently immobilized enzyme decreased the activity by 40-60% after 560 
chemical modifications, while the adsorbed enzyme improved the activity on p-561 
nitrophenylbutyrate (pNPB) by EDA modification (even by a 2-fold factor). Moreover, 562 
significant changes in the activity/pH profile and in the enzyme specificity by the chemical 563 
modification were observed. In a second research effort, the utilized enzyme was a 564 
commercial quimeric fosfolipase commercialized by Novozymes), Lecitase Ultra, 565 
immobilized in the same supports. Both immobilized preparations have been submitted to 566 
different individual or cascade chemical modifications (amination, glutaraldehyde or 2,4,6-567 
trinitrobenzensulfonic acid (TNBS) modification) in order to check the effect of these 568 
modifications on the catalytic features of the immobilized enzymes (including stability and 569 
substrate specificity under different conditions).141 As in the previously presented case, the 570 
effects of the chemical modifications strongly depend on the immobilization strategy used. 571 
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For example, using one immobilization protocol a modification improves activity, while for 572 
the other immobilized enzyme it is even negative. Most of the modifications presented a 573 
positive effect on some enzyme properties at least under certain conditions, and a negative 574 
effect under other conditions. For example, glutaraldehyde modification of immobilized or 575 
modified and aminated enzyme permitted to improve enzyme stability of both immobilized 576 
enzymes at pH 7 and 9 (around a 10-fold), but only the adsorbed aminated enzyme improved 577 
the enzyme stability at pH 5 by glutaraldehyde treatment. This occurred even though some 578 
intermolecular crosslinking could be detected via SDS-PAGE. Amination improved the 579 
stability of octyl-Lecitase, while it reduced the stability of the covalent preparation.141 580 
 Following a different amination strategy using an aminated polymer a nice proposal 581 
is described in a previous work.142 A poly-aminated dextran was site-specifically introduced 582 
on a lipase from Geobacillus thermocatenulatus (BTL2). The chosen site was Cys64, it is 583 
placed in the proximity of the region where the lid is allocated when the lipase exhibits its 584 
open and active form,112 and the modification was performed on two differently immobilized 585 
lipase preparations. This position of the enzyme was specifically modified by thiol-disulfide 586 
exchange with pyridyldisulfide poly-aminated-dextrans. If the enzyme was immobilized on 587 
cyanogen bromide agarose, the modification increased the activity by around a 2 fold factor 588 
versus aliphatic carboxylic esters, but if the substrate contained an aromatic carboxylic group 589 
the activity remained unchanged.142 If the enzyme was attached to glyoxyl-agarose (multipoint 590 
covalent attachment), a significant increase in activity was only observed using p-nitrophenyl 591 
butyrate. The stabilization of the open form of the lipase induced by the modification was 592 
shown by irreversible inhibition experiments. 593 
 594 
3.5. Chemical amination to improve the crosslinking of immobilized enzymes 595 
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 Chemical crosslinking of enzymes is a way to greatly increase their structure 596 
rigidity, and thus, their stability.16, 18, 143-145 From a very wide perspective, multipoint covalent 597 
attachment on a support may be considered a very intense crosslinking process, where the 598 
support is the crossliker reagent.31 This was treated in section 3.3.1. Here we will focus on the 599 
crosslinking using bi or multifunctional molecules of already immobilized enzymes. 600 
Intermolecular crosslinking is a quite complex process, as it must make a competition with 601 
one-point modification (if using homo-bifunctional reagents), and most important, only if 602 
there are reactive groups located on the appropriate distance (similar to the crosslinking 603 
reagent) the crosslinking will take place. This strategy is also valid to stabilize multimeric 604 
enzymes, if it involves all enzyme subunits.32 It seems obvious that an increase in the amount 605 
of reactive groups on the protein surface may be advantageous for both objectives. Moreover, 606 
most of the most used and effective crosslinkers are based on reaction between amino groups, 607 
as is the case of the glutaraldehyde.51, 146 Thus, amination of the enzyme surface could be a 608 
proper tool to achieve an intense intramolecular or intersubunit crosslinking. 609 
 However, although there are many reports on cross-linking of immobilized 610 
proteins,35 we have been able to find just one example where the amination was performed on 611 
previously aminated enzyme. This example was on penicillin G acylase previously multipoint-612 
immobilized on glyoxyl-agarose.64 After amination, the enzyme was submitted to full amino-613 
modification with one molecule or two molecules of glutaraldehdye per amino group, the 614 
excess of reactive was eliminated and both preparations were long term incubated to permit an 615 
intense crosslinking (crosslinking is a quite slow process, as it requires the reaction between 616 
two groups attached to a rigid structure, a protein surface). After 20 h of incubation, 617 
stabilization factors of more than 40 were found when using one glutaraldehyde molecule per 618 
amino group, while results were poorer using two glutaraldehyde molecules.64 The incubation 619 
pH value, 7 or 9, presented a marginal effect, suggesting the high reactivity of the amino-620 
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glutaraldehyde groups with another glutaraldehyde amino groups in a wide range of pH 621 
values. Using formaldehyde, stabilization did not take place, suggesting that this reactive may 622 
have a most complex crosslinking behavior.64 Using an excess of formaldehyde, similar 623 
stabilization factors were found,147 suggesting that formaldehyde require to form some multi-624 
fomaldehyde structures to give some crosslinking.148  625 
 626 
3.6. Chemical amination to improve the physical coating with anionic polymers 627 
 The coating of enzymes with polymers has been reported as an efficient way to 628 
improve the enzyme stability versus some inactivating causes.149, 150 For example, the enzyme 629 
may become stabilized versus interaction with interfaces, such gas bubbles gas produced by 630 
stirring (e.g., if adjusting the pH value is necessary) or gas bubbling (e.g., if oxygen needs to 631 
be supplied). It may also be used to prevent multimeric enzyme inactivation by subunit 632 
dissociation,151 to increase enzyme stability versus organic solvents by generating a certain 633 
partition, etc.35 Previous examples use chemical modifications, for example using aldehyde 634 
dextran, but this modification may be somehow complex, and may affect enzyme activity 635 
(chemical reaction, reduction step, etc). In this sense, the use of ionic polymers may be a 636 
simpler solution. 637 
 One requirement to use this strategy is that the polymer can coat the enzyme, and 638 
that the enzyme-polymer interaction may be strong enough to enable the use of this composite 639 
under a wide range of pH value without breaking the composite. In fact, in some instances, 640 
this stabilization of the polymer-enzyme composite has been achieved by using a chemical 641 
crosslinker,74 but in other cases this may not be possible, e.g., if the enzyme is inactivated by 642 
this treatment.75  643 
 Most of the examples dealing with coating enzymes with ionic polymers use 644 
polyethylenimine (see section 4 of this review) because most enzymes have an Ip too low to 645 
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become coated using polyanionic polymers under neutral pH values. Ionic exchange, as it has 646 
been previously stated, requires a multipoint ion exchange.132, 133 In this case, we intend that 647 
the full protein surface many be coated by the polymer. This may be harder that just the 648 
immobilization, which only involves a determined enzyme area. 649 
 This coating with anionic polymers may be easily achieved using previously 650 
chemically aminated enzyme: the protein will have a cationic nature in pH values as high as 651 
12 if total amination is achieved,40 permitting to have a very stable enzyme-anionic polymer 652 
composite. Although this strategy should work, we have been unable to find an example 653 
where aminated enzymes are coated using poly-ionic polymers, the only examples we have 654 
found are related to immobilization of enzymes on anionic supports (see section 3.3.3).62, 135-655 
137 However, as we thought that this application should work properly, we have decided to 656 
include this possibility in the present review. 657 
 658 
3.7. Chemical amination to improve their further modification with other compounds 659 
 In some instances, the researcher may intend to introduce some molecules on the 660 
enzyme surface to alter its physical properties, or alter their catalytic efficiency. The reaction 661 
with amino groups of the protein used to be one of the most used ones due to the good 662 
reactivity of amino groups with many reactive.152-155 However, if we really desire a massive 663 
modification of the protein surface, this may not be so simple, as the pK of the amino group in 664 
the lateral chain of Lys is 10.5, and this pK will be quite similar on medium exposed residues. 665 
The terminal amino groups may have a far lower pK value, but this group may only permit a 666 
one-point modification. This was the goal of a recent paper.66 The researches intended to 667 
modify the surface of the lipase B from Candida antarctica with succinic polyethyleneglycol 668 
via the carbodiimide route. Immobilized enzyme (on octyl Sepharose or Eupergit C) were 669 
used, to analyze the effect of the immobilization protocol. Modification of the native amino 670 
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groups of the enzyme did not produce a significant alteration ion the amount of the amino 671 
groups of the enzyme (just around 1 group per enzyme molecule could be modified). 672 
However, if the enzyme was previously aminated, around 14-15 PEG molecules could be 673 
introduced per enzyme molecule. As in other examples commented in other sections, it has 674 
been found that the effect of this modification depends on the immobilization protocol. For 675 
example, activity versus pNPP increased using CALB-octyl Sepharose while it decreased 676 
when using Eupergit C following amination and PEGylation. In hydrolysis of R/S methyl 677 
mandelate, enantioselectivity in this hydrolysis significantly improved after modification 678 
using the covalent preparation (from 7.5 to 20), while using octyl Sepharose almost had no 679 
effect.66  680 
 681 
3.8. Chemical amination of proteins to improve their usefulness “in vivo” 682 
 Covalently aminated enzymes, using polymers such as polyethylenimine or small 683 
amines attached to the carboxylic groups, have been used in vivo due to several advantages. 684 
 Regarding the preparation of antibodies versus small compunds, the use of aminated 685 
proteins have two main advantages. First, the modified protein has a different, usually more 686 
potent immunogenecity that unmodified protein.156, 157 Second, and related to the point 3.6 of 687 
this review, the larger amount and higher reactivity of the aminated enzymes, may permit to 688 
introduce a higher number of antigen moleculdss per carrier protein.158 689 
Regarding the use of proteins as a medicament the cationized protein is able to penetrate 690 
membranes in a more efficient way than the unmodified proteins.159, 160 691 
 Now we will make a rapid overview on some examples of these uses of amination of 692 
proteins. 693 
 3.8.1. Use of aminated proteins to raise antibodies versus small molecules. 694 
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 To raise antibodies versus small molecules, it is necessary to attach this small 695 
haptamers to large proteins, because if the size is under 5000 the immunologic response is 696 
very low or inexistent.  697 
 In the late 1980s, it was shown that a cationized form of bovine serum albumin 698 
produced by substituting the anionic side chain carboxylic groups with aminoethylamide 699 
groups possesses unique immunologic properties.157 It was possible to use 500 fold lower 700 
amount of cationized protein to reach the same immunogenic response. Moreover, antibodies 701 
were produced in response to administration of cationized protein but not using unmodified 702 
enzyme unless an adjuvant was used. It was speculated that the aminated protein may have a 703 
greater affinity for antigen-presenting cells or for the T cell receptor, or that the altered 704 
structure may enhance recognition of the molecule by APC and/or helper T cells.157 The 705 
authors tried to explain theses results investigating the uptake of unmodified and cationized 706 
serum albumin by splenic APC.156  Amination was performed at different degrees of 707 
carboxylic modification. An inverse correlation between the degree of cationization and the 708 
amounts of antigen needed for optimal T cell reactivity was observed. The results suggested 709 
that native albumin enters the cell by fluid phase pinocytosis, whereas aminated BSA enters 710 
by a nonspecific adsorptive mechanism. The different modes of cellular entry for the two 711 
molecules, nBSA and cBSA, resulting in a rapid uptake of aminated BSA. This was proposed 712 
to have important ramifications on T cell activation and immunoregulation. 713 
 In another paper, ethylenediamine modified bovine albumin was modified with 714 
aflatoxin B1 using a Mannich-type protocol, and utilized to raise antibodies versus aflatoxin 715 
B1, achieving a quicker immunological response and a similar sensitivity of antisera against 716 
AFB1 were observed, compared with immunization by AFB1-oxime-albumin.161 Later, a 717 
similar strategy was used to raise antibodies versus bisphenol A.162 Compared with non-718 
aminated protein, the aminated bovine serum albumin improved the efficiency of coupling and 719 
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enhanced the immune response against the target antigen. The sensitivity of antisera against 720 
bisphenol A was similar to the sera obtained using non-aminated protein.162 In a third 721 
research, dichlorvos was coupled with cationized bovine serum albumin using also using a 722 
method based on Mannich-type reaction, and utilized to produce a monoclonal antibody 723 
versus diclorvos.163  724 
 In a nice report, it was shown that combining double-chemically modified carrier 725 
proteins and hetero-functional cross-linkers allows preparing tailor-made hapten-protein 726 
carrier conjugates.158 The protein was aminated and further modified by different cross-linkers 727 
(hyper-activated proteins) at different conditions in order to control the conjugation ratio from 728 
1 to > 12 molecules of hapten per carrier protein. Finally, this novel strategy has been 729 
successfully used to develop antibodies against a short specific peptide corresponding to a one 730 
point mutation (D816V) of cKIT, which is a clinically relevant mutation related to 731 
mastocytosis and gastrointestinal stroma tumor.  732 
 733 
3.8.2. Improving the enzyme function in vivo 734 
 Proteins and enzymes may be used as medicaments. In other cases, enzymes are 735 
used as a way to make some studies on their effect on cells. In most of these cases, the 736 
enzymes need to be inside the cells to be useful, or to penetrate complex barriers, such as the 737 
brain barrier. 738 
 It has been demonstrated that proteins artificially cationized by chemical conjugation 739 
show efficient intracellular delivery via adsorptive-mediated endocytosis and then can exert 740 
their biological activity in cells.159 As the mammalian cell membrane possesses an abundance 741 
of negatively charged glycoproteins and glycosphingolipids, cationization of proteins is a 742 
reasonable choice to endow them with the ability for intracellular delivery.160  743 
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 One of the applications of amination of proteins has been the improvement of 744 
antibody penetration on cells and different tissues. Owing to the poor transport of monoclonal 745 
antibodies across either capillary or cell membrane barriers, drug delivery strategies are 746 
needed to target monoclonal antibodies to intracellular sites where proteins function. 747 
Aminated antibodies may be therapeutic and allow for intracellular immunization because 748 
their better penetration in cells. There are many examples of this strategy in literature. 749 
 The improved issue uptake of cationized immunoglobulin G was shown after 750 
intravenous administration relative to the uptake of native protein.164 The studies demonstrate 751 
that cationization of immunoglobulin greatly increases organ uptake of the plasma protein 752 
compared to native immunoglobulins, and suggests that cationization of monoclonal 753 
antibodies may represent a potential new strategy for enhancing the intracellular delivery of 754 
these proteins. The ratio of the volume of distribution of the 3H-cationized IgG compared 755 
to 3H-labeled native albumin ranged from 0.9 (testis) to 15.7 (spleen) in the rat and  in 756 
primates.164  757 
 In another study, polyclonal antibodies directed against a 16-amino acid synthetic 758 
peptide corresponding to amino acids 35-50 of the 116-amino acid rev protein of human 759 
immunodeficiency virus type 1 were used as a model of the effect of the amination on protein 760 
cell uptake.165  The study demonstrated that cationization results in enhanced endocytosis of 761 
the antibody and enhanced inhibition of HIV-1 replication, consistent with intracellular 762 
immunization of the rev protein. 763 
 In another paper, the cationization of a monoclonal antibody prepared against a 764 
synthetic peptide encoding the Asp13 point mutation of the ras proto-oncogenic p21 protein 765 
permitted to improve the uptake in vitro.166 While the 125I-labeled native D146 antibody 766 
uptake by MDA-MB231 human carcinoma cells was negligible, there was a marked increase 767 
in the endocytosis of the antibody following cationization. The in vivo organ uptake of the 768 
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cationized monoclonal antibody was increased relative to the native antibody; there was a 6-769 
fold increase in the systemic volume of distribution, a 58- fold increase in the systemic 770 
clearance of the cationized antibody from the plasma compartment, and a 9-fold reduction in 771 
the mean residence time of the cationized antibody as compared to the native D146 antibody.  772 
 The in vivo pharmacokinetics and efficacy of cationized human immunoglobulins in 773 
the human-peripheral blood lymphocytes-severe combined immune deficiency mouse model 774 
were evaluated in another study using the severe combined immunodeficient mouse 775 
transplanted with human lymphocytes and infected with human immunodeficiency virus 776 
(HIV)-1.167 Immunoglobulins from noninfected humans and from HIV-infected individuals 777 
were cationized. The pharmacokinetic analysis showed that the cationized immunoglobulins 778 
have a markedly reduced mean residence time and a marked increase in organ uptake 779 
compared to the native immunoglobulins. Treatment of HIV-infected severe combined 780 
immune deficiency mice that were transplanted with human lymphocytes demonstrated 781 
therapeutic efficacy for a 2-week treatment at a dose of 5 mg/kg cationized HIV immune 782 
globulin.167 783 
 In another study, the feasibility of cationizing the humanized 4D5 monoclonal 784 
antibody directed against the p185(HER2) oncogenic protein was analyzed to analyze its cell 785 
uptake.168 Native antibody was confined to the periplasma membrane space with minimal 786 
endocytosis into the cell. In contrast, robust internalization of the cationized 4D5 antibody by 787 
the SK-BR3 cells was demonstrated. The systemic volume of distribution of the cationized 788 
4D5 antibody was 11-fold greater than that of the native antibody 789 
 In another example, it was found that aminated goat colchicine-specific polyclonal 790 
immunoglobulin G and antigen binding fragment in plasma decreased more rapidly than the 791 
non-modified counterparts.169 In addition, there was a 74-fold increase in the volume of 792 
distribution and a 114-fold increase in the systemic clearance of aminated antibody with the 793 
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native one. Amination of colchicine-specific antiobibidy or their fragments increased the 794 
organ distribution and greatly altered their pharmacokinetics.169 795 
 In other cases, the amination has as objective to achieve the function of enzymes 796 
inside the cells to solve some problems, that is, use the enzymes as medicaments. For 797 
example, the successful prevention of hydrogen peroxide-induced damage to the rat jejunal 798 
mucosa by cationized catalase and compared to the protection achieved using unmodified 799 
enzyme.170 It was found that in all cases the cationized enzymes were superior to the native 800 
catalase in their shielding capability. A significant protection against Fe(II)/H2O2 and ascorbic 801 
acid/copper ion-mediated damage was obtained when the cationized enzymes were used. In 802 
the presence of glucose, native glucose oxidase failed to cause damage in the rat jejunal 803 
mucosa; however, the cationized enzyme caused profound tissue injury. These findings 804 
indicate the potential therapeutic merit of cationized enzymes for the treatment of pathological 805 
processes in the intestine, whenever oxidative stress is involved.170  806 
 In another research, the objective was to achieve hepatic delivery of catalase for the 807 
prevention of CCl 4-induced acute liver failure in mice, two types of cationized catalase 808 
composites were developed using ethylendiamine  (13.6 amino groups/molecule could be 809 
introduced) or hexylendiamine (introduction of 3.1/molecule).171 Aminated enzyme showed 810 
an increased binding to HepG2 cells, and were rapidly taken up by the liver. Hydrogen 811 
peroxide induced cytotoxicity in HepG2 cells was significantly prevented by preincubation of 812 
the cells with aminated enzyme. 813 
 Perhaps ribonucleases (RNases) are the most studied enzymes as therapeutics.  814 
Ribonucleases are potential anti-tumor drugs due to their cytotoxicity. A general model for the 815 
mechanism of the cytotoxic action of RNases includes the interaction of the enzyme with the 816 
cellular membrane, internalization, translocation to the cytosol, and degradation of ribonucleic 817 
acid.172 The cytotoxic properties of naturally occurring or engineered RNases correlate well 818 
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with their efficiency of cellular internalization and digestion level of cellular RNA. Cationized 819 
RNases are considered to adsorb to the anionic cellular surface by Coulombic interactions, and 820 
then become efficiently internalized into cells by an endocytosis-like pathway.173 Although 821 
chemically modified cationized RNases showed decreased ribonucleolytic activity, improved 822 
endocytosis and decreased affinity to the endogenous RNase inhibitor improve their ability to 823 
digest cellular RNA.  824 
 Toxic effects of aminated Streptomyces aureofaciens RNases Sa, Sa2, Sa3, are 825 
enhanced, indicating the major role of a cationic nature on the enzyme surface.174 Another 826 
study shows how carboxyl groups of bovine RNase A and human RNase 1 were modified 827 
with ethylenediamine by the carbodiimide route.175 The modified RNases were cytotoxic 828 
toward 3T3-SV-40 cells despite their decreased in ribonucleolytic activity. RNase inhibitor R1 829 
cannot eliminate their enzymatic activity, while native enzymes were completely inactivated 830 
by RI. The cytotoxicity correlated well with the net cationic residues. Cationic RNases were 831 
more efficiently adsorbed by the cells. In a more detailed study, they found that if modifying 5 832 
to 7 out of 11 carboxyl groups in RNase A, a maximum on cytotoxicity toward MCF-7 and 833 
3T3-SV-40 cells were found.176  834 
 Another application of aminated proteins is their use as carrier proteins for different 835 
drugs or peptides. For example, rat albumin was cationized with hexamethylenediamine, and 836 
the isoelectric point of the protein was raised from 5.5 to approximately 8.177 The aminated rat 837 
serum albumin was taken up by isolated rat or bovine brain microvessels, whereas native 838 
protein was not taken up by the capillaries in vitro. The brain volume of distribution of the 3H-839 
cationized rat serum albumin increased linearly over a 5-hr period after an intravenous 840 
injection of the isotope and reached a value of 46 ± 3 μl/g (mean ± S.E.) by 5 hr, whereas the 841 
brain volume of distribution of the 125I-native rat serum albumin was constant during the 5-hr 842 
time period (9.3 ± 0.7 μl/g, which is equal to the brain blood volume).. Therefore, cationized 843 
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rat albumin may be used in future studies that use the repetitive administration of cationized 844 
rat albumin chimeric peptides for the evaluation of the transport of these substances through 845 
the blood-brain barrier in vivo.177 846 
 In another example, bovine serum albumin was aminated with 847 
hexamethylenediamine or ethylenediamine to obtain cationized proteins and study the relation 848 
between physical properties and hepatic delivery.178 Aminated albumins were rapidly taken up 849 
by liver, but the protein modified using hexylenediamine showed a faster uptake than is using 850 
ethylenediamine, with a similar number of free NH2 groups, suggesting that the diamine 851 
reagent with a longer carboxyl side chain results in more efficient hepatic targeting. A low 852 
degree of amination is sufficient for efficient hepatic targeting of proteins.178  853 
 Another research used the cationic β-lactoglobulin as carrier. This protein was 854 
assayed as a bioavailability enhancer for poorly absorbed bioactive compounds.179 At most 11 855 
anionic amino acid residues of β-lactoglobulin were substituted by ethylenediamine, resulting 856 
in a highly cationic surface and significantly increased surface hydrophobicity. These changes 857 
improved also improved mucoadhesion.179  858 
 In other cases, amination of enzymes and proteins has been used to facilitate the 859 
study of proteins in living cells. In the post-genomic era, there is interest for developing 860 
methodologies that permit protein manipulation to analyze functions of proteins in living cells. 861 
For this purpose, techniques to deliver functional proteins into living cells are of great 862 
relevance and protein amination seems to be an efficient strategy. A method for efficient 863 
protein transduction into living cells in which a protein is simply cationized with PEI by 864 
limited chemical conjugation was described in an interesting paper.180 PEI-cationized proteins 865 
appeared to adhere to the cell surface by ionic charge interaction and then internalize into cells 866 
in a receptor- and transporter-independent fashion. Since PEI is an organic macromolecule 867 
with a high cationic-charge density, limited coupling with PEI results in endowment of 868 
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sufficient cationic charge to proteins without causing serious decline in their fundamental 869 
functions. A number of PEI-cationized proteins, such as ribonuclease (RNase), green 870 
fluorescent protein (GFP) and immunoglobulin (IgG), efficiently entered cells and functioned 871 
in the cytosol.180  872 
 The glutathione S-transferase-fused protein expression system has been extensively 873 
used to generate a large quantity of proteins and has served for functional analysis in vitro.  A 874 
novel approach for the efficient intracellular delivery of GST-fused proteins into living cells to 875 
expand their usefulness up to in vivo use has been intended using the amination of the enzyme 876 
to improve the enzyme penetrability.181 The glutathione S-transferase fused proteins were 877 
cationized by forming a complex with a polycationic polyethylenimine-glutathione conjugate. 878 
On screening of protein transduction, optimized PEI-glutathione conjugate for protein 879 
transduction was characterized by a partly oligomerized mixture of PEI with average 880 
molecular masses of 600 (PEI600) modified with multiple glutathiones, which could have 881 
sufficient avidity for glutathione S-transferase.181 These PEI-glutathione conjugates seem to 882 
be convenient molecular tools for protein transduction of widely used glutathione S-883 
transferase -fused proteins in in vitro studies 884 
 Another example is the artificial regulation of cell proliferation by protein 885 
transduction of the N-terminal domain (1-132 amino acids) of the simian virus 40 large T-886 
antigen, which inactivates retinoblastoma family proteins but no p53 has been intended by PEI 887 
modificatioin of this protein.182 To deliver proteins into cells, an indirect cationization method 888 
was used by forming a complex of biotynylated protein through disulfide bonds and PEI-889 
cationized avidin. Using this complex, the virus was transduced into the nucleus of confluent 890 
and quiescent Balb/c 3T3 cells and was found to be complexed with a cellular target protein, 891 
pRb. Furthermore, this viral protein produced transduction induced cell proliferation in spite 892 
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of confluent conditions. These results suggest that oncogene protein transduction technology 893 
has great potential for in vitro regulation of cell proliferation.182  894 
 In another original approximation, indirect protein amination using non-covalent 895 
interaction was evaluated for the transduction of proteins into living cells and for the 896 
expression of their functions in the cytosol. PEI-cationized avidin, streptavidin and protein G 897 
were prepared, and examined whether they could deliver biotinylated proteins and antibodies 898 
into living cells.183 PEI-avidin (and/or PEI-streptavidin) carried biotinylated GFPs into various 899 
mammalian cells very efficiently. A GFP variant containing a nuclear localization signal was 900 
found even in the cell nucleus. The addition of a biotinylated RNase A derivative mixed with 901 
PEI-streptavidin to a culture medium of 3T3-SV-40 cells resulted in remarkable cell growth 902 
inhibition, suggesting that the biotinylated RNase A derivative entered cells and digested 903 
intracellular RNA molecules. Furthermore, the addition of a fluorescein-labeled anti-S100C 904 
(beta-actin binding protein) antibody mixed with PEI-protein G to human fibroblasts resulted 905 
in the appearance of a fluorescence image of actin-like filamentous structures in the cells.183  906 
 Finally, amination has been proposed to recover the activity of proteins expressed as 907 
inclusion bodies. In a different approach, a reversibly aminated denatured protein through 908 
disulfide bonds is not only soluble in water but also able to fold to the native conformation in 909 
vitro.184 Taken together this and the easy penetration of aminated protein in cells, a novel 910 
method to deliver a denatured protein into cells and simultaneously let it fold to express its 911 
function within cells was presented. This "in-cell folding" method enhances the utility of 912 
recombinant proteins expressed in Escherichia coli as inclusion bodies. The strategy includes 913 
several steps: the recombinant proteins in inclusion bodies are solubilized by reversible 914 
cationization through cysteine residues by disulfide bonds with aminopropyl 915 
methanethiosulfonate or pyridyldithiopropionylpolyethylenimine and then incubated with 916 
cells without an in vitro folding procedure. This was shown using human tumor-suppressor 917 
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p53. Treatment of p53-null Saos-2 cells with reversibly cationized p53 revealed that all events 918 
examined as indications of the activation of p53 in cells, such as reduction of disulfide bonds 919 
followed by tetramer formation, localization into the nucleus, induction of p53 target genes, 920 
and induction of apoptosis of cells, occurred.184  921 
 922 
4. Physical amination of enzymes using aminated polymers 923 
 In the previous section, we have shown many examples where a protein was 924 
chemically attached to a poly-aminated polymer, usually chitosan or polyethyleneimine (PEI). 925 
This section will focus on the coating of the protein surface by polycationic polymers, but not 926 
in a covalent way, but simply by physical ionic exchange. The polymers may be quite large, 927 
even million of kDa, and that may facilitate the multipoint adsorption that is require to keep 928 
the polymer/enzyme interaction.132-134 929 
 PEI has been described to present some stabilizing effect on diverse proteins due to 930 
diverse causes: prevention of enzyme aggregation, prevention of lost of secondary structure, 931 
reduction of metal oxidation, prevention of multimeric enzyme dissociation, inactivation by 932 
deleterious substrates, etc.68, 69, 73, 75, 185  Some reports pointed that the stability-effect of poly-933 
ionic polymers did not really depend on their cationic or anionic nature of the polymer was not 934 
critical to get the stabilization, effect, stating that perhaps a direct electrostatic 935 
enzyme/polymer interaction was not required.67 However, considering that most enzymes may 936 
be adsorbed under the same conditions on PEI and dextran sulfate coated supports; it is not 937 
clear that this electrostatic interaction may be discarded.186  938 
 The effects of the polyamine polymer were not always positive on enzyme features. 939 
Quaternized polyamines (poly-N-alkyl-4-vinylpyridinium bromides suppress the 940 
thermoaggregation of glyceraldehyde-3-phosphate dehydrogenase but not thermodenaturation 941 
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of the enzyme.187 The adverse effect was reduced by the addition of sodium chloride, which 942 
destroyed the enzyme-polymer complex and resulted in a noticeable reactivation.  943 
 In another example, PEI was found to have not effect on the melting temperature of 944 
basic proteins while for the acidic ones there was a shift in the melting temperature towards 945 
lower temperatures.188 The secondary structures of the basic proteins were essentially the 946 
same in presence of the polymer, with none or a slight increase in the CD spectra. In the case 947 
of acidic proteins, the CD spectra were diminished mostly due to phase separation. Despite 948 
lowering the thermal stability of acidic proteins, PEI protected heart lactate dehydrogenase at 949 
an increasing oxidative stress. In another example, the addition of polyethyleneimine to 950 
chloroperoxidase from Caldariomyces fumago dramatically improved the stability of the 951 
enzyme towards peroxide dependent inactivation.189  952 
 Biosensors were fabricated at neutral pH by sequentially depositing the polycation 953 
polyethyleneimine (PEI), the stereoselective enzyme l-glutamate oxidase (GluOx) and poly-954 
ortho-phenylenediamine onto 125-μm diameter Pt wire electrodes.190 The presence of PEI 955 
produced a 10-fold enhancement in the detection limit for Glu (compared with the 956 
corresponding PEI-free configurations, without undermining the response time. Most 957 
remarkable was the finding that, although some designs of PEI-containing biosensors showed 958 
a 10-fold increase in linear region sensitivity to Glu, their oxygen dependence remained low.  959 
 However, the most interesting examples are when the enzyme coating with the 960 
polymer is a step in the development of an immobilized biocatalyst, as are some of the 961 
examples listed below. 962 
 963 
4.1. Immobilization on cation exchangers 964 
 Modification of the enzyme  using ionically exchanged poly-amines may permit to 965 
further immobilize the enzyme on a cation exchanger, when the free enzyme may have very 966 
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low affinity by its anionic surface (in fact, the enzymes used in this strategy will be coated 967 
with a cationic polymer, that way they should have also a anionic surface). 968 
 This has been exemplified by a single paper to date. Glutamate dehydrogenase from 969 
Thermus thermophilus and formate dehydrogenase from Pseudomonas sp. were coated with 970 
large PEI to prevent subunit dissociation.74 Both enzymes are very unstable at acidic pH 971 
values due to the rapid dissociation of their subunits (half-life of diluted preparations is few 972 
minutes at pH 4 and 25 °C).191, 192 The enzyme-PEI composites exhibited full activity after 973 
preparation. The enzyme-polymer composites were treated with glutaraldehyde to prevent 974 
enzyme/polymer dissociation at acidic pH value, that was the pH values range of higher 975 
interest in these enzymes. This step was performed by previously immobilizing the composite 976 
onto a weak cationic exchanger to prevent enzyme covalent aggregation. The composite could 977 
be very strongly, but reversibly, adsorbed on cationic exchangers.74 978 
 979 
4.2. Coating with poly-amine polymers before immobilization to prevent undesired 980 
interactions with the matrix 981 
 In other cases, the enzyme coating was just a first step in a longer immobilization 982 
strategy; the coating may increase the size of the enzyme, making their trapping easy, or 983 
preventing the interaction with deleterious interfaces. 984 
 Examples to improve the enzyme trapping in paper to be used in food packing may 985 
be found in the literature. To this goal, the microencapsulation of glucose oxidase from 986 
Aspergillus niger and laccase from Trametes versicolor in PEI with the goal of immobilizing 987 
these enzymes in paper substrates to develop biosensors and bioreactors.193 The technique 988 
caused a severe decrease (up to 65%) in the specific activities of both enzymes once 989 
microencapsulated. Microencapsulation improved the thermal stability of glucose oxidase at 990 
temperatures up to 60 °C due to stabilization of its active conformation but reduced the 991 
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thermal stability of laccase because of the increased coordination between PEI and copper 992 
atoms in the enzyme's active site. Glucose oxidase bioactive paper was fabricated, which 993 
could be potentially used as food packaging paper. In a further optimization, results using the 994 
laccase was improved, using a starch-based coating suspension.194 The use of 995 
microencapsulation allows for better activity retention in papers over time at room 996 
temperature (50% loss after 28 days) compared to papers modified with free laccase (50% loss 997 
after 4 days). Microcapsules also decrease the inhibition of laccase by azide. 998 
Another example is an interesting immobilization of enzymes using a “sandwich” 999 
strategy. Layered titanates have been employed to support active proteins, which have been 1000 
widely used in biocatalysis and bioelectrochemistry.  Their interest lay on their good 1001 
biocompatibility, nontoxicity, relatively high conductivity, and chemical and thermal 1002 
stability.195, 196 The titanate nanosheets are negatively charged, and stable in aqueous solution.  1003 
They can easily immobilize positively charged protein molecules, where a spontaneous 1004 
flocculation occurs and biomolecules are incorporated within the interlayer space of layered 1005 
structure. However, this did not occur if the enzyme has an anionic surface, that is, with most 1006 
of the proteins. This paper shows how the preliminary coating of the enzyme with PEI can be 1007 
used to immobilized the enzyme on Layered titanates.197 The native structures of proteins 1008 
were retained after immobilizing although a significant difference in microstructures was 1009 
observed among these composites. The amounts of immobilized proteins depend on the 1010 
enzyme, were up to ~70 % wt. for lysozyme, 37 % wt. for bovine serum albumin and 21.5 % 1011 
wt. for lipase from Candida rugosa. These composites were stable under neutral and weakly 1012 
acidic condition, and only releases <10 % proteins at pH under 4. These composites are 1013 
reusable, and the residual activities of immobilized enzymes are 68 % for lysozyme and 61 % 1014 
for lipase after 10 recycles. 1015 
 1016 
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4.3. Generation of artificial environments on immobilized enzymes 1017 
 Polyaminated polymers, like PEI, chitosan, polyalylmine, etc are quite hydrophilic, 1018 
their cationic nature may permit to recover the immobilized enzyme molecules of a very 1019 
hydrophilic shell that can produce some partition of   hydrophobic compounds, like gases, 1020 
organic solvents, etc, enabling the preparation of biocatalysts with improved stability in this 1021 
media. 1022 
 The strategy may be used for enzymes immobilized on preexisting supports, or 1023 
enzymes to be immobilized via the CLEA technology. 1024 
 One of the enzymes that has been subject to more studies using this stabilization 1025 
strategy is penicillin G acylase. This enzyme has many potential uses, hydrolysis of 1026 
antibiotics, resolution of racemic mixtures or synthesis of antibiotics.198 In many instances, the 1027 
enzyme needs to be used in organic medium, and the enzyme is not very stable under these 1028 
conditions. Even much stabilized immobilized enzymes via multipoint covalent attachment 1029 
have reduced application on some of these reactions.199 Thus, the stabilization of this enzyme 1030 
versus the deleterious effects of organic solvents is a key point for their applicability.200 In a 1031 
first approach, this stabilized enzyme was co-immobilized with PEI, submitted to successive 1032 
modification with aldehyde dextran and PEI.34 In an effort to further improve the enzyme 1033 
stability, sulfate dextran was also used, to generate a thick shell of “poly-ammonium sulfate” 1034 
that were able to stand even 95% of organic solvents like tetraglyme when the original 1035 
immobilized enzyme only can be used at a maximum of 60%, and with a lower operational 1036 
stability.201, 202 Even more interestingly, this derivatives presented a higher activity, 1037 
confirming that the random coil structure of the polymers avoid the promotion of diffusion 1038 
barriers. These preparations permitted to perform some reactions under conditions where the 1039 
untreated immobilized preparations exhibited a low stability, like  hydrolysis of penicillin G 1040 
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acylase in the presnce of organic solvent,203 enantioselective synthesis of phenylacetamides,204 1041 
or the synthesis of amides of high pK amines.205  1042 
 The co-aggregation of penicillin acylase, PEI and dextran sulfate permitted to 1043 
prepare crosslinked enzyme aggregates with also significantly improved properties in the 1044 
presence of organic solvents.206 This biocatalyst presented better behavior in organic solvents 1045 
than the more thermostable glyoxyl-agarose biocatalyst.207  1046 
 Stabilization of oxygen labile enzymes has been also achived by the salting out 1047 
effect, using coCLEAs of PEI and enzyme.  Oxygen labile nitrilases have been stabilized this 1048 
way versus oxygen inactivation.71 While the nitrilases lost 50-100% of their activity upon 1049 
exposure to oxygen for 40 h, the PEI co-aggregates of the nitrilases were much more oxygen-1050 
tolerant The nitrilase from Pseudomonas fluorescens EBC 191, in particular, retained its full 1051 
activity upon exposure to oxygen for 40 h.  1052 
 1053 
4.4. Improved preparation of CLEAs 1054 
 Polyaminated polymers have found several advantages in the preparation of 1055 
crosslinking enzyme aggregates (CLEAs). First, as commented in the point above, co-1056 
aggregation with PEI (combined or not with sulfate dextran) is able to generate a hydrophilic 1057 
environment around the enzyme, producing partition of solvent or oxygen. In this point we 1058 
will focus on the second advantage: it may be used to solve the problems generated in the 1059 
crosslinked step of proteins having just some few Lys superficial residues, or it may just be 1060 
used to have a more intensively crosslinked CLEA particle. 1061 
 The strategy was first established using the enzyme glutarayl acylase from 1062 
Pseudomonas sp., enzyme that as previously described in this review, is quite poor in 1063 
superficial Lys residues.102 Glutaryl acylase may be precipitated using polyethylene glycol, 1064 
but the further treatment of the aggregate particles with glutaraldehyde did not permit to 1065 
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crosslink the enzyme molecules, that re-dissolved when eliminating the precipitant reagent.128 1066 
Co-precipitating the enzyme and PEI, the cross-linking between the very reactive and 1067 
abundant primary amino groups of the PEI and the few primary amino groups on the enzyme 1068 
surface is favored, and the aggregates remain insolubilized in the absence of any precipitant. 1069 
The enzyme /PEI CLEA maintained more than 60% of its initial activity after 72 h of 1070 
incubation at 45 °C, whereas the soluble enzyme was fully inactivated in only 2.5 h of 1071 
incubation under the same conditions.  1072 
 A second example was using lipases. Standard CLEAs preparation using commercial 1073 
preparations of lipases from Alcaligenes sp. and Candida antarctica (fraction B) is not fully 1074 
effective, some leakage of enzyme from the CLEA can be observed, and the SDS-PAGE from 1075 
those preparations reveals that many enzyme molecules have not cross-linked properly.124 The 1076 
co-precipitation of the lipases with poly-ethyleneimine or PEI-sulfate dextran mixtures 1077 
permitted to get fully physically stable CLEAs, with higher stability in the presence of organic 1078 
solvents. Very interestingly, the conditions of precipitation and the nature of the polymers 1079 
permitted to significantly alter the lipases activity, enantio-selectivity and specificity.  1080 
 Lipases were also the subject of other studies. The lipase from Serratia marcescens 1081 
was co-aggregated with PEI.129 Optimum temperature was increased from 50 °C to 60 °C after 1082 
immobilization, and its thermal stability was also significantly improved.This coCLEA 1083 
showed excellent operational stability in its repeated use in aqueous-toluene biphasic system 1084 
for asymmetric hydrolysis of trans-3-(4′-methoxyphenyl) glycidic acid methyl ester (MPGM), 1085 
without significant inactivation after 10 rounds of repeated use. 1086 
 Another lipase immobilized using coCLEAs with PEI was the enzyme from 1087 
recombinant Geotrichum sp.208 These coCLEAs maintained more than 65% of relative 1088 
hydrolysis degree after incubation in the range of 50-55 °C for 4 h and maintain more than 1089 
85% of relative hydrolysis degree after being treated by acetone, tert-butyl alcohol and octane 1090 
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for 4 h. They were applied to hydrolyze fish oil for enrichment of polyunsaturated fatty acids 1091 
successfully and increased hydrolysis degree to 42% from 12% by free lipase. After five batch 1092 
reactions, PEI-CLEAs still maintained 72% of relative hydrolysis degree.  1093 
 Not only lipases have been immobilized following this coCLEA strategy. L-1094 
Aminoacylase from Aspergillus melleus was co-aggregated with polyethyleneimine and 1095 
subsequently cross-linked with glutaraldehyde to obtain aminoacylase-polyethyleneimine 1096 
cross-linked enzyme aggregates.209  This biocatalyst expressed 75% activity recovery and 81% 1097 
aggregation yield, and improved enzyme stability. Its enantioselectivity was the highest for 1098 
hydrolysis of amino acid amides; was moderate for hydrolysis of N-acetyl amino acids and 1099 
was the worse for hydrolysis of amino acid esters. It retained more than 92% of the initial 1100 
activity after five consecutive batches of (RS)-homophenylalanine hydrolysis suggesting an 1101 
adequate operational stability of the biocatalyst. 1102 
 1103 
4.5. Tuning catalytic properties enzymes by coating their surfaces with poly-amine 1104 
polymer coated 1105 
 Physical coating of enzymes with PEI has been used in some instances to improve 1106 
enzyme properties, mainly lipases due to the facility to modulate their properties. The physical 1107 
coating is far simpler than the chemical modification, and in some instances may become as 1108 
effective (and even more in some instances). 1109 
 In a first report, the properties of the most popular commercial biocatalyst lipase of 1110 
lipase, Nozovym 435, were modulated by coating with different ionic polymers. PEI coated 1111 
Novozym 435 improved is activity versus 3-phenylglutaric dimethyl diester by a 3-fold 1112 
factor.139  1113 
Later, using a covalently immobilized preparation of the same lipase instead of the 1114 
commercial one, it was shown that PEI modification on immobilized lipases greatly enhanced 1115 
 46 
the enantioselectivity of the immobilized enzyme in the kinetic resolution of (±)-2-hydroxy-1116 
phenylacetic acid methyl ester.210 The enantiomeric ratio went from E=1.5 (without coating) 1117 
to E>100 (ee>99%). Using a covalently immobilized lipase from Candida rugosa, the E went 1118 
from 8 (without coating) to 20 after PEI coating. Moreover, this coating strategy improved the 1119 
activity in some instances, the stability at high temperatures or in the presence of high co-1120 
solvent.  1121 
 Immobilized Lecitase Ultra (a chimeric fosfolipase commercialized by Novozymes), 1122 
has also been coated with different poly ionic polymers.211 The effect of the coating depended 1123 
on the immobilization protocol, however, the PEI coating generally produced a significant 1124 
increase in enzyme activity, in some cases even by more than a 30-fold factor (using the octyl-1125 
Lecitase at pH 5 in the hydrolysis of methyl phenyl acetate). The rate of irreversible inhibition 1126 
of the covalent preparation using diethyl p-nitrophenylphosphate did not increase after PEI 1127 
coating suggesting that the increase in Lecitase activity is not a consequence of the 1128 
stabilization of the open form of Lecitase.212  1129 
 In a further development, PEI was not used to just coat the enzyme surface, but to 1130 
freeze the open conformation of Lecitase induced by the presence of a detergent (SDS).213 1131 
Coating the immobilized enzyme with polyethylenimine in aqueous buffer (PEI) produced a 1132 
3-fold increase in enzyme activity. However, in the presence of 0.1 % SDS (v/v), this coating 1133 
produced a 50-fold increase in enzyme activity. Using irreversible inhibitors, it could be 1134 
shown that the PEI/SDS-covalent immobilized -Lecitase preparation presented its catalytic Ser 1135 
more exposed to the reaction medium than the unmodified CNBr-Lecitase, suggesting that the 1136 
enzme open form was somehow stabilized.212  1137 
 1138 
5. Genetic amination 1139 
5.1. Use of poly-Arg or poly-Lys tags 1140 
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 Protein fusion tags have been developed as indispensable tools for protein 1141 
expression, purification, and the design of functionalized surfaces or artificially bifunctional 1142 
proteins.214 A recent review215 has summarizes how positively or negatively charged polyionic 1143 
fusion peptides with or without an additional cysteine can be used as protein tags for protein 1144 
expression and purification, for matrix-assisted refolding of aggregated protein, and for 1145 
coupling of proteins either to technologically relevant matrices or to other proteins.  1146 
 Immobilized enzyme orientation may play a critical role on the features of the 1147 
enzyme.216 By one side, this protein area will be the most involved one in the enzyme/support 1148 
interaction, being the most improved/worsened by the immobilization.217-220 By other side, this 1149 
may define the access of large substrates or ligands to this active center,221-225 or the 1150 
communication between the active center of the enzyme and an electrode.221, 226-230   1151 
 Site directed mutagenesis is the most efficient tools to achieve this site directed 1152 
immobilization, via introduction of specific groups on desired areas of the protein.37 Usually, 1153 
this orientation is achieved using a Cys inserted in the desired region, and immobilized on a 1154 
support bearing a disulfide groups.217-220 Other popular strategy is the use of poly-His tags,228, 1155 
231 or generation of His pairs,232 and immobilization on immobilized metal chelates matrices. 1156 
Other tools have been also utilized to get this oriented fixation of enzymes on supports. 1157 
 In this review, we will try to focus on how this Poly-cationic tags may be used for 1158 
protein immobilization.  1159 
 1160 
 5.1.1. Purification/immobilization using cationic tags, 1161 
 Most enzymes have an ionic surface nature that makes them unable to become 1162 
adsorbed on cationic exchangers, and that may be used as a way to purify proteins that can be 1163 
adsorbed on this kind of ionic exchangers. This may be achieved by the introduction of 1164 
cationic tags/domains on the target protein.215, 233-239  1165 
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 Thus, some examples on the of usage of poly-Lys or poly-Arg may be found in the 1166 
literature to obtain the one step purification and immobilization of enzymes on cation 1167 
exchangers. It has been shown that a poly-lysine tag facilitates protein purification and 1168 
refolding processes  1169 
  For example, a poly-lysine (10 lysine residues) tagged cyclodextrin 1170 
glycosyltransferase from Bacillus macerans and used to immobilize the enzyme on 1171 
Sulphopropyl–Sepharose a cation-exchange resin.44 Enzyme activity was fully retained after 1172 
immobilization. Though the poly-lysine-mediated immobilization is reversible, the binding 1173 
force is strong enough to block protein leakage from the solid support at neutral and basic pH. 1174 
The authors pointed out that the method needs improvements since the enzyme was releaased 1175 
at acidic pH values. Perhaps the use of polyanionic polymers could be a likely solution for this 1176 
problem.186 This biocatalyst was used to produce α-cyclodextrin from soluble starch.240 1177 
Destabilization of CGTase by poly-lysine fusion and immobilization onto a cation exchanger 1178 
was detected. However, α- cyclodextrin productivity of 539.4 g l-1 h-1 was obtained with 2% 1179 
soluble starch and the operational half-life of the packed-bed enzyme reactor was estimated 12 1180 
days at 25°C and pH 6.0.  1181 
 In an interesting paper, surface-modified iron oxide particles were used for the 1182 
simultaneous purification and immobilization of Bacillus stearothermophilus aminopeptidase 1183 
II (BsAPII) tagged C-terminally with either tri- or nona-lysines.241 The adsorption strength 1184 
depended on the size of the tag. Three Lys permitted purification to near homogeneity by the 1185 
carboxylated magnetic particles, but it was not easy to elute the adsorbed Lys9 protein from 1186 
the matrix. Immobilization improved the stability of the enzyme. That way, the Lys 9 tag-1187 
aminopeptidase could be recycled ten times without a significant loss of enzyme activity.242 1188 
 In another example, carboxyehtyl chitosan magnetic nanoparticles were used to 1189 
purify small ubiquitin-like modifier, a protease derived from Saccharomyces cerevisiae. The 1190 
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enzyme was fused with a poly lysine tag containing 10 lysine residues at its C-terminus.43 The 1191 
lysine-tagged protease can be simply purified by magnetite nanoparticles from cell extracts 1192 
with very high purity in just one-step. A poly-Arg tag has been used in other cases. For 1193 
example, D-xylose isomerase from Escherichia coli was fused with a 10-arginine tag) at its C-1194 
terminus.243 The fusion protein XIR10 was purified to a high purity and immobilized by a 1195 
single step of cation exchange chromatography. The immobilization to the cation exchanger 1196 
has a small effect on the enzymatic function. 1197 
 In another research, a minichaperone polypeptide was fused with a poly-arginine (10 1198 
residues).244 This chimeric peptide was purified through a single step of cation exchange 1199 
chromatography with high purity. The purified chaperone was efficiently immobilized on the 1200 
cation exchanger and applied to the refolding of Bacillus macerans cyclodextrin 1201 
glycosyltransferase, which was expressed as inclusion body in recombinant E. coli.  1202 
 1203 
 5.1.2. Improving covalent immobilization via poly cationic tags 1204 
 The addition of a Poly-Lys tag may be also advantageous to reach a further covalent 1205 
immobilization of the peptide after ionic exchange. The idea would be similar to the use of 1206 
heterofunctional supports: first the enzyme is adsorbed, second the covalent reaction takes 1207 
place due to the very high apparent concentrations of reactive groups on both support and 1208 
adsorbed protein.50 Using this strategy, it was found that the covalent immobilization of a 1209 
protein onto the maleic anhydride-alt-methyl vinyl ether copolymers, via the formation of 1210 
amide bonds, occurred in moderate yields under aqueous conditions. This was exemplified 1211 
using two genetically modified HIV-1 capsid p24 proteins, RH24 and RH24K.245 The addition 1212 
of a six lysine unit tag at the COOH-terminus of RH24K greatly improved the grafting 1213 
reaction which could take place under many different experimental conditions. The course of 1214 
the reaction was controlled by electrostatic attractive forces between the protein and the 1215 
 50 
negatively charged polymer, as the chemical binding was more efficient at low ionic strength. 1216 
This explanation was later confirmed using a petide.246 The grafting reaction was improved by 1217 
adding a sequence of three positively charged amino acids (lysine or arginine) at the amino 1218 
terminus of the peptide. The arginine tag was more efficient than the lysine tag for enhancing 1219 
the immobilization reaction, proving that the effect was due to an electrostic driving force.  1220 
 1221 
 5.1.3. Using of poly-Lys to direct the covalent immobilization of proteins to 1222 
modulate its catalytic behavior 1223 
 It has been shown on some papers and recent reviews how the control of the area of 1224 
the protein involved in the reaction with the support may produce different changes (or 1225 
prevent some changes that should occur), being this tool a very powerful strategy for 1226 
improving enzyme performance in different reactions whose yield depend on the catalytic 1227 
performance of the catalyst.25, 31, 36  1228 
 The control of the immobilization of penicillin G acylase using a poly Lys tag is the 1229 
only example that we have been able to find regarding the use of poly Lys tag to reach this 1230 
goal. This biocatalyst was used for the kinetically controlled synthesis of different beta-1231 
lactamic antibodies. In this reaction strategy, the use of an activated acyl donor permits to 1232 
reach transient maximum yields, and this yields are determined by the rate of synthesis and 1233 
rates of activated acyl donor and product hydrolysis.25, 247  1234 
 To achieve this, a tag of three lysines alternating with three glycines was added to 1235 
the C-terminal end of the β chain of penicillin G acylase. This enzyme was then immobilized 1236 
to glyoxyl agarose.59 As glyoxyl agarose only immobilized enzymes via several points,55, 56 1237 
this new very rich area in Lys drives the immobilization by this area, even though the 1238 
increment on total amino groups was under 10%, even permitting to immobilize the enzyme at 1239 
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pH 9.59 The immobilization of this enzyme the catalytic properties of the immobilized 1240 
derivative on kinetically synthesis of cefamandole and cefonicid.248  1241 
 1242 
 5.1.4. Other uses of chimeric enzymes/poly-Lys tags 1243 
 Poly-Lysine tags may have some other applications. For example,  this strategy was 1244 
used to the efficient production of the intact glucagon-like peptide-1 using a recombinant E. 1245 
coli system, avoiding degradation.249 The peptide was fused to a 6-lysine tag, ubiquitin and the 1246 
peptide in a row. Solid-phase refolding of chimeric protein inclusion body using a cation 1247 
exchanger led to a refolding yield over 90%. Finally, the cleavage of the refolded protein with 1248 
ubiquitin-specific protease 1 gave an authentic form of the desired peptide. 1249 
 In other cases, poly-caitonic tags have been used to improve the expression of a 1250 
hyper-expressd enzyme. They can favor the solubility of these hyper-expressed proteins. For 1251 
example, Lipase B from Candida antarctica was fused with various polycationic amino acid 1252 
tags and expressed in E. coli in order to increase a soluble expression level.250 The 10-arginine 1253 
and 10-lysine tags fused at the C-terminal of CalB significantly increased the solubility of the 1254 
lipase by five- to ninefold, relative to the case of the native enzyme expressed in a 1255 
recombinant E. coli. 1256 
 1257 
5.2. Modification of the protein surface 1258 
 In other cases, the increase on Lys residues is not performed using a tag, but by 1259 
selecting different regions to increase the density of Lys groups in the specific region on 1260 
which we intend to use to immobilize the enzyme, or disperse along the protein surface, if we 1261 
just intend to increase the cationic groups on the surface.  1262 
 In immobilization, to take full advantage of this Lys enrichment, the immobilization 1263 
should be based on multipoint processes, that way the factor directing the immobilization will 1264 
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be the density of reactive groups in one protein area and not the reactivity of a special residue 1265 
or its global amount. Among the support for covalent immobilization, glyoxyl supports fulfill 1266 
this requirement.55, 56 For reversible immobilization, most of the supports follow this 1267 
multipoint interaction to fix the enzyme to the support.31, 134  1268 
 1269 
 5.2.1. Improvement of the multipoint covalent attachment 1270 
 The strategy of improving the multipoint covalent attachment on glyoxyl supports 1271 
have been developed using Penicillin G acylase from E. coli as a model enzyme. The 1272 
researchers chose a region of the enzyme that was already very rich in Lys resides and 1273 
introduced there additional Lys residues.58 The immobilization rate was increased by more 1274 
than a 10 fold factor when compared to the wild enzyme, even though the number of overall 1275 
external Lys was increased by less than 10%. This confirmed that the immobilization was 1276 
mainly performed via the region where the new Lys residues had been introduced. The 1277 
immobilized mutant enzyme showed improved stability on thermal or cosolvent induced 1278 
inactivations with stabilization factors ranging from 4 to 11 compared to that of the native 1279 
enzyme immobilized on glyoxyl-agarose following the same protocol.58 Considering the 1280 
stabilization obtained by the immobilization of the wild type enzyme (near to 10,000),251 the 1281 
final stabilization factors achieved with this strategy were impressive. 1282 
  In another research, the enzyme (horseradish peroxidase) and the support (a 1283 
modified polyethersulfone matrix presenting aldehyde residues) were changed.252 The 1284 
researchers replaced arginine residues on the face of glycan-free recombinant horseradish 1285 
peroxidase opposite to the active site by lysines. These conservative Arg-to-Lys substitutions 1286 
provide a means of multipoint covalent immobilization such that the active site will always 1287 
face away from the immobilization matrix. One triple and one pentuple mutant were generated 1288 
by substitution of solvent-exposed arginines on the "back" of the polypeptide (R118, R159 1289 
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and R283) and of residues known to influence stability (K232 and K241).252 Oriented a 1290 
modified polyethersulfone matrix presenting aldehyde residues immobilization was 1291 
demonstrated using the modified polyethersulfone membrane; the protein was forced to 1292 
orientate its active site away from the membrane and towards the bulk solution phase. The 1293 
reversion of K283R mutation permitted to improve enzyme stability, the quadruple mutant 1294 
regained some stability over its mutant counterparts. A moderate improvement on the 1295 
immobilization rate of the mutant enzymes on CNBr-activated Sepharose™ was noted with 1296 
increased lysine content. This support was able to fix the enzyme via just one point, usually 1297 
involving the most reactive group on the protein. However, only marginal gains in solvent 1298 
stability resulted from immobilization on this latter matrix. The authors conclude that a 1299 
directional and oriented immobilization of horseradish peroxidase mutants onto 1300 
polyethersulfone membrane has been achieved with excellent retention of catalytic activity.252  1301 
 A more directed strategy was later proposed. First, one Cys residue was introduced 1302 
on different regions of the enzyme penicillin G acylase, to find the area that was more 1303 
determinant for enzyme stability.253 The immobilization was performed on an epoxy support, 1304 
because Cys was by far the most reactive amino group on a protein and that was enough to 1305 
direct the enzyme. The mutant enzyme where the Cys was in the position β380 was the one 1306 
that gave the highest PGA stabilization values. In a second round of site-directed mutagenesis, 1307 
that region was further enriched in 4 additional lysine residues, and the resulting immobilized 1308 
derivative was 1500-fold more stable than the same protein variant uni-punctually 1309 
immobilized through position β380.253  1310 
 It is expected that in the near future, this strategy may be extended to more enzymes. 1311 
 1312 
5.2.2. Site directed immobilization: controlling enzyme catalytic features 1313 
 1314 
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 In other cases, the objective was more to have a fully oriented immobilized enzyme 1315 
than to improve the multipoint covalent attachment or the enzyme stability. This was the case 1316 
of the immobilization of mutant penicillin G acylase enzymes enriched in Lys areas in the area 1317 
opposite to the active center.254 The objective was to improve the behavior of the enzyme in 1318 
kinetically controlled synthesis of semi-synthetic β-lactam antibiotics. Native enzyme 1319 
immobilized mainly near to the active center, and that seemed to generate some steric 1320 
hindrances to the entry of the nucleophile produceing a severe worsening in its properties. 1321 
Different mutants with an increasing number of Lys were designed and immobilized onto 1322 
glyoxyl agarose. These immobilized Lys enriched mutants have similar performances to the 1323 
free enzyme. Later, they show this differential immobilization of the enzyme using tryptic 1324 
digestion of the immobilized enzymes followed by liquid chromatography-tandem mass 1325 
spectrometry.255 1326 
 1327 
 5.2.3. Improvement of immobilization in anionic exchangers 1328 
 While using chemical amination there is at least one example of the use of amination  1329 
to improve the immobilization on cation exchangers (see section  3.3.3), we have not been 1330 
able to find a similar example using genetic amination. In fact, and this may serve as a proof 1331 
of concept, there is one example where genetic increment on carboxylic groups of the surface 1332 
of penicillin G acylase improves its immobilization on anion exhangers.63  1333 
 1334 
5.2.4. Improvement of intermolecular crosslinking 1335 
 We have not been able to find any papers concerning the use of enzymes with 1336 
enriched areas in Lys residues and the stabilization of this enzyme by using intermolecular 1337 
crosslinkers. However, in a similar way as when using chemical amination (see section 3.5 of 1338 
this review), this should permit to greatly improve the enzyme crosslinking by increasing the 1339 
prospects of having two residues of the protein at the right distance.64 In fact, this can be even 1340 
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more favorable than chemical amination, where it is only possible to get a general enrichment 1341 
on the enzyme surface of amino groups, using the carboxylic groups of the enzyme. Now, 1342 
using site-directed mutagenesis and if the enzyme has a well described structure, it is possible 1343 
to place the new Lys residues on the right position to permit the enzyme crosslinking, a 1344 
critical point to get an intramolecular crossliking.144 1345 
 1346 
 5.2.5. Improvement of coating with anionic polymers 1347 
 Again, we have not found examples where the enrichment in Lys residues of the 1348 
protein is used to facilitate the adsorption of cationic polymers on their surface. Using the 1349 
enzyme penicillin G acylase, there is, however, an example of enrichment on carboxy groups 1350 
of the enzyme surface to improve the adsorption of cationic polymers on the enzyme 1351 
surface,256 and in section 3.6 the chemical amination to this goal is presented.62 Perhaps, 1352 
although this coating may have very good effects on enzyme performance (se section 4 of this 1353 
review), it is considered too sophisticated to improve the interaction via site-directed 1354 
mutagenisis. 1355 
 1356 
 5.2.6. Other uses 1357 
  As discussed in section 3, cationized enzymes have a higher potential to 1358 
penetrate cell membranes and system barriers. Together with the previously presented 1359 
chemical modifications, this increase in surface cations may be also achieved via site-directed 1360 
modification. For example, Ribonuclease Sa (pI = 3.5) from Streptomyces aureofaciens and its 1361 
3K (D1K, D17K, E41K) (pI = 6.4) and 5K (3K + D25K, E74K) (pI = 10.2) mutants were 1362 
tested for cytotoxicity.257 The 5K mutant was cytotoxic to normal and v-ras-transformed 1363 
NIH3T3 mouse fibroblasts, while RNase Sa and 3K were not. The cytotoxic 5K mutant 1364 
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preferentially attacks v-ras-NIH3T3 fibroblasts, suggesting that mammalian cells expressing 1365 
the ras-oncogene are potential targets for ribonuclease-based drugs. 1366 
 1367 
Conclusion and future trends 1368 
 1369 
 This review has shown the high interest that the amination of enzymes and proteins has 1370 
with views towards improving their behavior in vitro as industrial biocatalysts, but also in vivo 1371 
when using proteins as carriers or as medicaments.  1372 
 Amination has proved to be very useful to improve enzyme immobilization via 1373 
multipoint covalent attachment or cation exchange, to improve intramolecular crosslinking, to 1374 
improve enzyme stability, or to improve intermolecular crosslinking which is a critical step in 1375 
the preparation of CLEAs. The amination also increases the immunogenicity and potential to 1376 
penetrate cell walls, enabling the use of some enzymes as biocides, improving the production 1377 
of antibodies, or just permitting to study the role of certain proteins in vivo after introduction 1378 
in the cell.  1379 
In some cases, amination may produce drastic changes in enzyme stability, activity or 1380 
selectivity/specificity . Considering the change of ionic interactions on the enzyme surface, a 1381 
negative effect should be expected. However in many instances the effect is positive.. 1382 
 Most examples cited in this review use chemical or physical amination. This may be 1383 
derived from the rapid preparation of the modified enzymes using these techniques, and the 1384 
relatively simple preparation of a collection of enzymes having different modification degrees, 1385 
mainly if a solid phase modification may be performed. Perhaps this may be the best solution 1386 
to alter enzyme properties such as selectivity of specificity, because the current knowledge on 1387 
enzyme dynamics cannot give the exact groups to be modified to mimic the effects using site-1388 
directed modification. Moreover, this may be a first and rapid step to evaluate if the amination 1389 
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really permits to improve enzyme immobilization. However, these strategies in general will 1390 
produce a general modification of the enzyme surface, and that may not be the best solution in 1391 
some instances. 1392 
Site-directed mutagenesis is a slower technique, which requires expertise in fields 1393 
different from those required for enzyme chemical modification or enzyme immobilization. 1394 
However, together with the advantages derived from the fact that the modified enzymes will 1395 
be always produced in this way (once the mutation has been introduced), this strategy may 1396 
give some further possibilities. For example, only site directed genetic amination may permit 1397 
to get a site-directed immobilization of enzymes on supports such as glyoxyl or cation 1398 
exchangers, or to select the modified groups in a way that the introduction of an 1399 
intramolecular crosslinker may be facilitated. This may be an explanation of the relatively low 1400 
amount of examples where genetic amination has been used, even though these examples have 1401 
shown the very high improvement that this amination may have in the behavior of the final 1402 
biocatalyst. In fact, it has never been used to improve the chemical reactivity versus 1403 
crosslinking reagents, although chemical amination has proved that this may be a critical point 1404 
to use this strategy. 1405 
Thus, we are before a clear example of the convenience of a close collaboration 1406 
between experts in scientific areas apparently quite far in the design of biocatalysts. If this is 1407 
achieved, it seems obvious that the genetic amination should be a future way of improving 1408 
enzymes and proteins to be used as biocatalysts, but also as medicaments or protein carriers. 1409 
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